1
|
Zhu Z, Bo-Ran Ho B, Chen A, Amrhein J, Apetrei A, Carpenter TO, Lazaretti-Castro M, Colazo JM, McCrystal Dahir K, Geßner M, Gurevich E, Heier CA, Simmons JH, Hunley TE, Hoppe B, Jacobsen C, Kouri A, Ma N, Majumdar S, Molin A, Nokoff N, Ott SM, Peña HG, Santos F, Tebben P, Topor LS, Deng Y, Bergwitz C. An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Kidney Int 2024; 105:1058-1076. [PMID: 38364990 DOI: 10.1016/j.kint.2024.01.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 12/23/2023] [Accepted: 01/08/2024] [Indexed: 02/18/2024]
Abstract
Pathogenic variants in solute carrier family 34, member 3 (SLC34A3), the gene encoding the sodium-dependent phosphate cotransporter 2c (NPT2c), cause hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Here, we report a pooled analysis of clinical and laboratory records of 304 individuals from 145 kindreds, including 20 previously unreported HHRH kindreds, in which two novel SLC34A3 pathogenic variants were identified. Compound heterozygous/homozygous carriers show above 90% penetrance for kidney and bone phenotypes. The biochemical phenotype for heterozygous carriers is intermediate with decreased serum phosphate, tubular reabsorption of phosphate (TRP (%)), fibroblast growth factor 23, and intact parathyroid hormone, but increased serum 1,25-dihydroxy vitamin D, and urine calcium excretion causing idiopathic hypercalciuria in 38%, with bone phenotypes still observed in 23% of patients. Oral phosphate supplementation is the current standard of care, which typically normalizes serum phosphate. However, although in more than half of individuals this therapy achieves correction of hypophosphatemia it fails to resolve the other outcomes. The American College of Medical Genetics and Genomics score correlated with functional analysis of frequent SLC34A3 pathogenic variants in vitro and baseline disease severity. The number of mutant alleles and baseline TRP (%) were identified as predictors for kidney and bone phenotypes, baseline TRP (%) furthermore predicted response to therapy. Certain SLC34A3/NPT2c pathogenic variants can be identified with partial responses to therapy, whereas with some overlap, others present only with kidney phenotypes and a third group present only with bone phenotypes. Thus, our report highlights important novel clinical aspects of HHRH and heterozygous carriers, raises awareness to this rare group of disorders and can be a foundation for future studies urgently needed to guide therapy of HHRH.
Collapse
Affiliation(s)
- Zewu Zhu
- Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA; Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Bryan Bo-Ran Ho
- Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Alyssa Chen
- Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA; Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts, USA
| | - James Amrhein
- Pediatric Endocrinology and Diabetes, School of Medicine Greenville Campus, University of South Carolina, Greenville, South Carolina, USA
| | - Andreea Apetrei
- Caen University Hospital, Department of Genetics, UR7450 Biotargen, Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, OSCAR Network, Caen, France
| | - Thomas Oliver Carpenter
- Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Marise Lazaretti-Castro
- Division of Endocrinology, Escola Paulista de Medicina-Universidade Federal de Sao Paulo (EPM-UNIFESP), Sao Paulo, Brazil
| | - Juan Manuel Colazo
- Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA
| | - Kathryn McCrystal Dahir
- Division of Endocrinology, Program for Metabolic Bone Disorders, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Michaela Geßner
- Pediatric Nephrology, Children's and Adolescents' Hospital, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Evgenia Gurevich
- Schneider Children's Medical Center of Israel, Pediatric Nephrology Institute, Petach Tikva, Israel; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
| | | | - Jill Hickman Simmons
- Department of Pediatrics, Division of Endocrinology and Diabetes, Vanderbilt University School of Medicine, Vanderbilt University, Nashville, Tennessee, USA
| | - Tracy Earl Hunley
- Division of Pediatric Nephrology, Vanderbilt University Medical Center, Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee, USA
| | - Bernd Hoppe
- Division of Pediatric Nephrology, Department of Pediatrics, University of Bonn, Bonn, Germany
| | - Christina Jacobsen
- Division of Endocrinology, Harvard Medical School, Boston, Massachusetts, USA
| | - Anne Kouri
- Pediatric Nephrology, University of Minnesota, Minneapolis, Minnesota, USA
| | - Nina Ma
- Section of Pediatric Endocrinology, Children's Hospital Colorado, Aurora, Colorado, USA; Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Sachin Majumdar
- Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Arnaud Molin
- Caen University Hospital, Department of Genetics, UR7450 Biotargen, Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, OSCAR Network, Caen, France
| | - Natalie Nokoff
- Department of Pediatrics, Section of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Susan M Ott
- Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Helena Gil Peña
- Department of Pediatrics, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain
| | - Fernando Santos
- Department of Pediatrics, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain
| | - Peter Tebben
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA; Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA
| | - Lisa Swartz Topor
- Division of Pediatric Endocrinology, Hasbro Children's Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
| | - Yanhong Deng
- Yale School of Public Health, New Haven, Connecticut, USA
| | - Clemens Bergwitz
- Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA.
| |
Collapse
|
2
|
Bourgois A, Bizaoui V, Colson C, Vincent-Devulder A, Molin A, Gérard M, Gruchy N. Phenotypic and genotypic characterization of 1q21.1 copy number variants: A report of 34 new individuals and literature review. Am J Med Genet A 2024; 194:e63457. [PMID: 37881147 DOI: 10.1002/ajmg.a.63457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Revised: 09/01/2023] [Accepted: 10/12/2023] [Indexed: 10/27/2023]
Abstract
Recurrent 1q21.1 copy number variants (CNVs) have been associated with a wide spectrum of clinical features, ranging from normal phenotype to moderate intellectual disability, with congenital anomalies and dysmorphic features. They are often inherited from unaffected parents and the pathogenicity is difficult to assess. We describe the phenotypic and genotypic data for 34 probands carrying CNVs in the 1q21.1 chromosome region (24 duplications, 8 deletions and 2 triplications). We also reviewed 89 duplications, 114 deletions and 5 triplications described in the literature, at variable 1q21.1 locations. We aimed to identify the most highly associated clinical features to determine the phenotypic expression in affected individuals. Developmental delay or learning disabilities and neuropsychiatric disorders were common in patients with deletions, duplications and triplications of 1q21.1. Mild dysmorphic features common in these CNVs include a prominent forehead, widely spaced eyes and a broad nose. The CNVs were mostly inherited from apparently unaffected parents. Almost half of the CNVs were distal, overlapping with a common minimal region of 1.2 Mb. We delineated the clinical implications of 1q21.1 CNVs and confirmed that these CNVs are likely pathogenic, although subject to incomplete penetrance and variable expressivity. Long-term follow-up should be performed to each newly diagnosed case, and prenatal genetic counseling cautiously discussed, as it remains difficult to predict the phenotype in the event of an antenatal diagnosis.
Collapse
Affiliation(s)
- Alexia Bourgois
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, UR 7450 BioTARGen, FHU G4 Genomics, Caen, France
| | | | - Cindy Colson
- CHU Lille, University of Lille, EA7364, Lille, France
| | - Aline Vincent-Devulder
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, UR 7450 BioTARGen, FHU G4 Genomics, Caen, France
| | - Arnaud Molin
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, UR 7450 BioTARGen, FHU G4 Genomics, Caen, France
| | - Marion Gérard
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, UR 7450 BioTARGen, FHU G4 Genomics, Caen, France
| | - Nicolas Gruchy
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, UR 7450 BioTARGen, FHU G4 Genomics, Caen, France
| |
Collapse
|
3
|
Massier M, Doco-Fenzy M, Egloff M, Le Guillou X, Le Guyader G, Redon S, Benech C, Le Millier K, Uguen K, Ropars J, Sacaze E, Audebert-Bellanger S, Apetrei A, Molin A, Gruchy N, Vincent-Devulder A, Spodenkiewicz M, Jacquin C, Loron G, Thibaud M, Delplancq G, Brisset S, Lesieur-Sebellin M, Malan V, Romana S, Rio M, Marlin S, Amiel J, Marquet V, Dauriat B, Moradkhani K, Mercier S, Isidor B, Arpin S, Pujalte M, Jedraszak G, Pebrel-Richard C, Salaun G, Laffargue F, Boudjarane J, Missirian C, Chelloug N, Toutain A, Chiesa J, Keren B, Mignot C, Gouy E, Jaillard S, Landais E, Poirsier C. 3q29 duplications: A cohort of 46 patients and a literature review. Am J Med Genet A 2024:e63531. [PMID: 38421086 DOI: 10.1002/ajmg.a.63531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 12/15/2023] [Accepted: 12/22/2023] [Indexed: 03/02/2024]
Abstract
Duplications of the 3q29 cytoband are rare chromosomal copy number variations (CNVs) (overlapping or recurrent ~1.6 Mb 3q29 duplications). They have been associated with highly variable neurodevelopmental disorders (NDDs) with various associated features or reported as a susceptibility factor to the development of learning disabilities and neuropsychiatric disorders. The smallest region of overlap and the phenotype of 3q29 duplications remain uncertain. We here report a French cohort of 31 families with a 3q29 duplication identified by chromosomal microarray analysis (CMA), including 14 recurrent 1.6 Mb duplications, eight overlapping duplications (>1 Mb), and nine small duplications (<1 Mb). Additional genetic findings that may be involved in the phenotype were identified in 11 patients. Focusing on apparently isolated 3q29 duplications, patients present mainly mild NDD as suggested by a high rate of learning disabilities in contrast to a low proportion of patients with intellectual disabilities. Although some are de novo, most of the 3q29 duplications are inherited from a parent with a similar mild phenotype. Besides, the study of small 3q29 duplications does not provide evidence for any critical region. Our data suggest that the overlapping and recurrent 3q29 duplications seem to lead to mild NDD and that a severe or syndromic clinical presentation should warrant further genetic analyses.
Collapse
Affiliation(s)
- Marie Massier
- Department of Genetics, Reims University Hospital, Reims, France
| | - Martine Doco-Fenzy
- Department of Genetics, Reims University Hospital, Reims, France
- Department of Genetics, Nantes University Hospital, Nantes, France
| | - Matthieu Egloff
- Department of Genetics, Poitiers University Hospital, Poitiers, France
- University of Poitiers, INSERM, LNEC, Department of Genetics, Poitiers University Hospital, Poitiers, France
| | - Xavier Le Guillou
- Department of Genetics, Poitiers University Hospital, Poitiers, France
- University of Poitiers, CNRS, LMA, Department of Genetics, Poitiers University Hospital, Poitiers, France
| | | | - Sylvia Redon
- Department of Genetics, Brest University Hospital, Brest, France
- Intellectual Disability Reference Center, Department of Pediatrics, Brest University Hospital, Brest, France
- University of Brest, Inserm, EFS, UMR 1078, GGB, Brest, France
| | - Caroline Benech
- University of Brest, Inserm, EFS, UMR 1078, GGB, Brest, France
| | | | - Kevin Uguen
- Department of Genetics, Brest University Hospital, Brest, France
- Intellectual Disability Reference Center, Department of Pediatrics, Brest University Hospital, Brest, France
- University of Brest, Inserm, EFS, UMR 1078, GGB, Brest, France
| | - Juliette Ropars
- Intellectual Disability Reference Center, Department of Pediatrics, Brest University Hospital, Brest, France
| | - Elise Sacaze
- Intellectual Disability Reference Center, Department of Pediatrics, Brest University Hospital, Brest, France
| | - Séverine Audebert-Bellanger
- Department of Genetics, Brest University Hospital, Brest, France
- Intellectual Disability Reference Center, Department of Pediatrics, Brest University Hospital, Brest, France
| | - Andreea Apetrei
- University of Normandy, UNICAEN, RU7450 BioTARGen, Caen University Hospital, Department of Genetics, Reference Center for Developmental Disorders and Malformative Syndromes, Anddi-Rares Network, Caen, France
| | - Arnaud Molin
- University of Normandy, UNICAEN, RU7450 BioTARGen, Caen University Hospital, Department of Genetics, Reference Center for Developmental Disorders and Malformative Syndromes, Anddi-Rares Network, Caen, France
| | - Nicolas Gruchy
- University of Normandy, UNICAEN, RU7450 BioTARGen, Caen University Hospital, Department of Genetics, Reference Center for Developmental Disorders and Malformative Syndromes, Anddi-Rares Network, Caen, France
| | - Aline Vincent-Devulder
- University of Normandy, UNICAEN, RU7450 BioTARGen, Caen University Hospital, Department of Genetics, Reference Center for Developmental Disorders and Malformative Syndromes, Anddi-Rares Network, Caen, France
| | | | - Clémence Jacquin
- Department of Genetics, Reims University Hospital, Reims, France
| | - Gauthier Loron
- Department of Neonatal Medicine and Pediatric Intensive Care, University of Reims Champagne-Ardenne, CReSTIC, Reims University Hospital, Reims, France
| | - Marie Thibaud
- Department of Pediatrics, American Memorial Hospital, Reims, France
| | | | - Sophie Brisset
- Constitutional Genetics Unit, Versailles Hospital, Le Chesnay, France
| | - Marion Lesieur-Sebellin
- Department of Genomic Medicine of Rare Disorders, Necker Hospital, APHP Center, University Paris Cité, Paris, France
| | - Valérie Malan
- Department of Genomic Medicine of Rare Disorders, Necker Hospital, APHP Center, University Paris Cité, Paris, France
| | - Serge Romana
- Department of Genomic Medicine of Rare Disorders, Necker Hospital, APHP Center, University Paris Cité, Paris, France
| | - Marlène Rio
- Department of Genomic Medicine of Rare Disorders, Necker Hospital, APHP Center, University Paris Cité, Paris, France
| | - Sandrine Marlin
- Department of Genomic Medicine of Rare Disorders, Necker Hospital, APHP Center, University Paris Cité, Paris, France
| | - Jeanne Amiel
- Department of Genomic Medicine of Rare Disorders, Necker Hospital, APHP Center, University Paris Cité, Paris, France
| | - Valentine Marquet
- Department of Cytogenetics, Clinical Genetics and Reproductive Biology, Limoges University Hospital, Limoges, France
| | - Benjamin Dauriat
- Department of Cytogenetics, Clinical Genetics and Reproductive Biology, Limoges University Hospital, Limoges, France
| | | | - Sandra Mercier
- Department of Genetics, Nantes University Hospital, Nantes, France
| | - Bertrand Isidor
- Department of Genetics, Nantes University Hospital, Nantes, France
| | - Stéphanie Arpin
- Department of Genetics, Tours University Hospital, UMR 1253, iBrain, University of Tours, Inserm, Tours, France
| | | | - Guillaume Jedraszak
- Constitutional Genetic Laboratory, University Hospital of Amiens & UR4666 HEMATIM, University of Picardie Jules Verne, Amiens, France
| | - Céline Pebrel-Richard
- Cytogenetic Medical Department; UIC Cytogenetics of Rare Diseases and Reproduction (GRUIC ADERGEN), Rare Diseases Reference Center (CRMR): Developmental Anomalies and Malformative Syndromes in the Auvergne Region, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Gaëlle Salaun
- Cytogenetic Medical Department; UIC Cytogenetics of Rare Diseases and Reproduction (GRUIC ADERGEN), Rare Diseases Reference Center (CRMR): Developmental Anomalies and Malformative Syndromes in the Auvergne Region, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Fanny Laffargue
- Department of Medical Genetics, UIC ADDIR (GRIUC ADERGEN), Constitutive Reference Center CLAD South-East: Developmental anomalies and malformative syndromes, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - John Boudjarane
- Medical Genetics Department, Timone Enfants University Hospital, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - Chantal Missirian
- Medical Genetics Department, Timone Enfants University Hospital, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - Nora Chelloug
- Department of Medical Genetics, Toulouse University Hospital, Toulouse, France
| | - Annick Toutain
- Department of Genetics, Tours University Hospital, UMR 1253, iBrain, University of Tours, Inserm, Tours, France
| | - Jean Chiesa
- Department of Genetics, Nimes, University Hospital, Nimes University Hospital, Nimes, France
| | - Boris Keren
- Department of Genetics, APHP Sorbonne University, Paris, France
| | - Cyril Mignot
- Department of Genetics, APHP Sorbonne University, Paris, France
| | - Evan Gouy
- Department of Genetics, Hospices Civils de Lyon, Lyon, France
| | - Sylvie Jaillard
- Department of Cytogenetics and Cell Biology, Rennes university hospital, Rennes, France
| | - Emilie Landais
- Department of Genetics, Reims University Hospital, Reims, France
| | - Céline Poirsier
- Department of Genetics, Reims University Hospital, Reims, France
| |
Collapse
|
4
|
Bouzemane A, Vignot E, Derain Dubourg L, De Mul A, Molin A, Chapurlat R, Fontanges E, Delsart D, Akbari A, Huang SHS, McIntyre CW, Bacchetta J, Lemoine S. Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy. J Clin Endocrinol Metab 2024; 109:e488-e494. [PMID: 37843399 DOI: 10.1210/clinem/dgad608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2023] [Revised: 09/04/2023] [Accepted: 10/11/2023] [Indexed: 10/17/2023]
Abstract
CONTEXT X-linked hypophosphatemia (XLH) is a rare genetic disorder that results in increased plasma levels of fibroblast growth factor 23 (FGF23). Several studies have demonstrated a direct association between FGF23 and cardiovascular mortality in cohorts of patients with chronic renal failure. However, in patients with XLH, studies on the cardiovascular impact of the disease are rare, with contradictory results. OBJECTIVE The aim was to assess whether the disease led to an increased cardiovascular risk. METHODS We conducted a single-center retrospective observational study on a local cohort of adult patients with XLH. The primary endpoint was a composite endpoint of the frequency of left ventricular hypertrophy (LVH) or presence of high blood pressure. Our secondary objectives were to assess echocardiographic, pulse wave velocity, and central blood pressure data as other markers of CV health. Independently of this cohort, tissue sodium content with magnetic resonance imaging was studied in 2 patients with XLH before and after burosumab. RESULTS Twenty-two patients were included. Median serum phosphate was 0.57 (0.47-0.72) mmol/L and FGF23 94 pg/L (58-2226). Median blood pressure was 124 (115-130)/68 (65-80) mm Hg, with only 9% of patients being hypertensive. A majority of patients (69%) had no LVH, only 1 had a left ventricular mass >100 g/m² and 25% of patients had left ventricular remodeling. Pulse wave velocity was normal in all patients. No differences in skin and muscle sodium content were observed before and after burosumab in the 2 patients who underwent sodium magnetic resonance imaging. CONCLUSION We found no elevated risk of developing hypertension or LVH in patients with XLH.
Collapse
Affiliation(s)
- Alexandre Bouzemane
- Hospices Civils de Lyon, Nephrology, hypertension renal and functional exploration, Hôpital Edouard Herriot, 69003, Lyon, France
| | | | - Laurence Derain Dubourg
- Hospices Civils de Lyon, Nephrology, hypertension renal and functional exploration, Hôpital Edouard Herriot, 69003, Lyon, France
| | - Aurélie De Mul
- Reference centre for rare calcium and phosphorus diseases, paediatric rheumatology and dermatology, rare diseases network, OSCAR, ORKID, ERKNet BOND, HFME, Bron 69029, France
| | - Arnaud Molin
- Genetic department, Centre Hospitalier Universitaire de Caen, Caen, 14033, France
| | - Roland Chapurlat
- Rheumatology Department, CHU Edouard-Herriot, 69003 Lyon, France
| | | | - Daphne Delsart
- Cardiology functional explorations, Hopital Edouard-Herriot, 69003 Lyon, France
| | - Alireza Akbari
- Canada Kidney clinical research unit, London Health Sciences Centre, East London, ON, N6A 5W9Canada
| | - Shih Han Susan Huang
- Canada Kidney clinical research unit, London Health Sciences Centre, East London, ON, N6A 5W9Canada
| | - Christopher W McIntyre
- Canada Kidney clinical research unit, London Health Sciences Centre, East London, ON, N6A 5W9Canada
| | - Justine Bacchetta
- Reference centre for rare calcium and phosphorus diseases, paediatric rheumatology and dermatology, rare diseases network, OSCAR, ORKID, ERKNet BOND, HFME, Bron 69029, France
- University of Lyon, CarMeN Laboratory, IRIS Team, INSERM, INSERM1033, INRA, INSA Lyon, 69100, Villeurbanne, France
- INSERM 1033, prevention of bone diseases, 69008 Lyon, France
| | - Sandrine Lemoine
- Hospices Civils de Lyon, Nephrology, hypertension renal and functional exploration, Hôpital Edouard Herriot, 69003, Lyon, France
- Reference centre for rare calcium and phosphorus diseases, paediatric rheumatology and dermatology, rare diseases network, OSCAR, ORKID, ERKNet BOND, HFME, Bron 69029, France
- University of Lyon, CarMeN Laboratory, IRIS Team, INSERM, INSERM1033, INRA, INSA Lyon, 69100, Villeurbanne, France
| |
Collapse
|
5
|
Racine C, Denommé-Pichon AS, Engel C, Tran Mau-Them F, Bruel AL, Vitobello A, Safraou H, Sorlin A, Nambot S, Delanne J, Garde A, Colin E, Moutton S, Thevenon J, Jean-Marçais N, Willems M, Geneviève D, Pinson L, Perrin L, Laffargue F, Lespinasse J, Lacaze E, Molin A, Gerard M, Lambert L, Benigni C, Patat O, Bourgeois V, Poe C, Chevarin M, Couturier V, Garret P, Philippe C, Duffourd Y, Faivre L, Thauvin-Robinet C. Multiple molecular diagnoses in the field of intellectual disability and congenital anomalies: 3.5% of all positive cases. J Med Genet 2023; 61:36-46. [PMID: 37586840 DOI: 10.1136/jmg-2023-109170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2023] [Accepted: 07/27/2023] [Indexed: 08/18/2023]
Abstract
PURPOSE Wide access to clinical exome/genome sequencing (ES/GS) enables the identification of multiple molecular diagnoses (MMDs), being a long-standing but underestimated concept, defined by two or more causal loci implicated in the phenotype of an individual with a rare disease. Only few series report MMDs rates (1.8% to 7.1%). This study highlights the increasing role of MMDs in a large cohort of individuals addressed for congenital anomalies/intellectual disability (CA/ID). METHODS From 2014 to 2021, our diagnostic laboratory rendered 880/2658 positive ES diagnoses for CA/ID aetiology. Exhaustive search on MMDs from ES data was performed prospectively (January 2019 to December 2021) and retrospectively (March 2014 to December 2018). RESULTS MMDs were identified in 31/880 individuals (3.5%), responsible for distinct (9/31) or overlapping (22/31) phenotypes, and potential MMDs in 39/880 additional individuals (4.4%). CONCLUSION MMDs are frequent in CA/ID and remain a strong challenge. Reanalysis of positive ES data appears essential when phenotypes are partially explained by the initial diagnosis or atypically enriched overtime. Up-to-date clinical data, clinical expertise from the referring physician, strong interactions between clinicians and biologists, and increasing gene discoveries and improved ES bioinformatics tools appear all the more fundamental to enhance chances of identifying MMDs. It is essential to provide appropriate patient care and genetic counselling.
Collapse
Affiliation(s)
- Caroline Racine
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
| | - Anne-Sophie Denommé-Pichon
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Camille Engel
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
| | - Frederic Tran Mau-Them
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Ange-Line Bruel
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Antonio Vitobello
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Hana Safraou
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Arthur Sorlin
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
| | - Sophie Nambot
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Julian Delanne
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
| | - Aurore Garde
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
| | - Estelle Colin
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
| | - Sébastien Moutton
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
| | - Julien Thevenon
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
| | - Nolwenn Jean-Marçais
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
| | - Marjolaine Willems
- Centre de Référence "Anomalies du Développement syndromes malformatifs" Occitanie, Service de Génétique Médicale, Hôpital Arnaud de Villeneuve, Montpellier, France
| | - David Geneviève
- Centre de Référence "Anomalies du Développement syndromes malformatifs" Occitanie, Service de Génétique Médicale, Hôpital Arnaud de Villeneuve, Montpellier, France
- INSERM U1183, Université de Montpellier, Montpellier, France
| | - Lucile Pinson
- Centre de Référence "Anomalies du Développement syndromes malformatifs" Occitanie, Service de Génétique Médicale, Hôpital Arnaud de Villeneuve, Montpellier, France
| | - Laurence Perrin
- Genetic Department, Robert-Debré Hospital Department of Genetics, Paris, France
| | - Fanny Laffargue
- Service de Génétique médicale, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - James Lespinasse
- Unité de Génétique médicale, Centre Hospitalier Métropole Savoie, Chambery, France
| | - Elodie Lacaze
- Department of Medical Genetics, Hospital Group Le Havre, Le Havre, France
| | - Arnaud Molin
- Service de Génétique, University Hospital Centre Caen, Caen, France
| | - Marion Gerard
- Service de Génétique, University Hospital Centre Caen, Caen, France
| | | | | | - Olivier Patat
- Department of Medical Genetics, University Hospital Centre Toulouse, Toulouse, France
| | - Valentin Bourgeois
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Charlotte Poe
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Martin Chevarin
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Victor Couturier
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Philippine Garret
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Christophe Philippe
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Yannis Duffourd
- Functional Unity of Innovative Diagnosis for Rare Diseases, University of Burgundy, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Laurence Faivre
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| | - Christel Thauvin-Robinet
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon Centre de Genetique, Dijon, France
- Inserm UMR1231 team GAD, University of Burgundy, Dijon, France
| |
Collapse
|
6
|
Méaux MN, Harambat J, Rothenbuhler A, Léger J, Kamenicky P, Soskin S, Boyer O, Boros E, D'Anella P, Mignot B, Gebhart M, Vic P, Richard N, Thivichon-Prince B, Francou B, Linglart A, Bacchetta J, Molin A. Genotype-phenotype Description of Vitamin D-dependent Rickets 1A: CYP27B1 p.(Ala129Thr) Variant Induces a Milder Disease. J Clin Endocrinol Metab 2023; 108:812-826. [PMID: 36321535 DOI: 10.1210/clinem/dgac639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Revised: 10/26/2022] [Indexed: 11/07/2022]
Abstract
INTRODUCTION Vitamin D-dependent rickets type 1A (VDDR1A) is a rare genetic disease associated with loss-of-function variations in the gene encoding the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1). Phenotype-genotype correlation is unclear. Long-term outcome data are lacking. The objective of this study was to describe characteristics and outcomes to search for a phenotype-genotype correlation. METHODS We retrospectively collected clinical data, genetic features, and outcomes from 24 genetically confirmed cases from 10 French centers; results are presented as median (min-max). RESULTS Clinical symptoms at diagnosis (age, 1.5 [0.5-8.7] years) were mainly bone and neurological abnormalities, and laboratory data showed hypocalcemia (1.97 [1.40-2.40] mmol/L), hypophosphatemia (-3.4 [-13.4 to (-)0.2] SD score for age), low 25OHD and low 1,25(OH)2D3, secondary hyperparathyroidism with PTH at 6.6 (1.3-13.7) times the upper limit for normal (ULN; PTH expressed as ULN to homogenize data presentation), and increased alkaline phosphatase (1968 [521-7000] IU/L). Bone radiographs were abnormal in 83% of patients. We identified 17 variations (11 missense, 3 frameshift, 2 truncating, and 1 acceptor splice site variations) in 19 families (homozygous state in 58% [11/19]). The partial loss-of-function variation p.(Ala129Thr) was associated with a milder phenotype: older age at diagnosis, higher serum calcium (2.26 vs 1.85 mmol/L), lower PTH (4.7 vs 7.5 ULN), and lower alkaline phosphatase (759 vs 2082 IU/L). Patients were treated with alfacalcidol. Clinical (skeletal, neurological), biochemical, and radiological outcomes were satisfactory, and complications occurred if there was bad adherence. CONCLUSION Overall, our findings highlight good outcomes under substitutive treatment and the need of a closer follow-up of eyes, teeth, kidneys, and blood pressure in VDDR1A.
Collapse
Affiliation(s)
- Marie-Noëlle Méaux
- CHU de Bordeaux, Service de Néphrologie Pédiatrique, Centre de Référence des Maladies Rénales Rares Sorare, 33 000 Bordeaux, France
- CHU de Lyon, Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques, 69 500 Bron, France
- INSERM, UMR 1033, Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, 69 008 Lyon, France
| | - Jérôme Harambat
- CHU de Bordeaux, Service de Néphrologie Pédiatrique, Centre de Référence des Maladies Rénales Rares Sorare, 33 000 Bordeaux, France
| | - Anya Rothenbuhler
- Centre de Référence des Maladies Rares du Calcium et du Phosphate, filière OSCAR, France
- Assistance Publique-Hôpitaux de Paris, Université Paris Saclay, INSERM, Service d'Endocrinologie et Diabète de l'enfant, Unité Physiologie et Physiopathologie Endocrinienne, Hôpital Bicêtre Paris Saclay, 94270 Le Kremlin-Bicêtre, France
| | - Juliane Léger
- Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Robert Debré, Endocrinologie Diabétologie Pédiatrique, 75 019 Paris, France
| | - Peter Kamenicky
- Assistance Publique-Hôpitaux de Paris, Hôpital Kremlin Bicêtre, Service d'Endocrinologie et de Biologie de la Reproduction, 94270 Le Kremlin-Bicêtre, France
| | - Sylvie Soskin
- CHU de Strasbourg, Service d'Endocrinologie Pédiatrique, 69 091 Strasbourg, France
| | - Olivia Boyer
- Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, CRMR MARHEA, Institut Imagine, Université Paris Cité, 75015 Paris, France
| | - Emese Boros
- Hôpital Universitaire des enfants Reine Fabiola, Service d'Endocrinologie Pédiatrique, 1020 Bruxelles, Belgique
| | | | - Brigitte Mignot
- CHU de Besançon, Service d'Endocrinologie Pédiatrique, 25000 Besançon, France
| | - Maite Gebhart
- CHU de Besançon, Service d'Endocrinologie Pédiatrique, 25000 Besançon, France
| | - Philippe Vic
- CH de Cornouailles, Service de Pédiatrie, 29000 Quimper, France
| | - Nicolas Richard
- CHU de Caen, Service de Génétique, EA7450 Biotargen, 14033 Caen, France
| | | | - Bruno Francou
- Assistance Publique-Hôpitaux de Paris, Hôpital Kremlin-Bicêtre, Laboratoire de génétique moléculaire, 94270 Le Kremlin-Bicêtre, France
| | - Agnès Linglart
- Centre de Référence des Maladies Rares du Calcium et du Phosphate, filière OSCAR, France
- Assistance Publique-Hôpitaux de Paris, Université Paris Saclay, INSERM, Service d'Endocrinologie et Diabète de l'enfant, Unité Physiologie et Physiopathologie Endocrinienne, Hôpital Bicêtre Paris Saclay, 94270 Le Kremlin-Bicêtre, France
| | - Justine Bacchetta
- CHU de Lyon, Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques, 69 500 Bron, France
- INSERM, UMR 1033, Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, 69 008 Lyon, France
- Centre de Référence des Maladies Rares du Calcium et du Phosphate, filière OSCAR, France
- Centre de Référence des Maladies Rénales Rares Néphrogones, filière ORKID, France
| | - Arnaud Molin
- Centre de Référence des Maladies Rares du Calcium et du Phosphate, filière OSCAR, France
- CHU de Caen, Service de Génétique, EA7450 Biotargen, 14033 Caen, France
| |
Collapse
|
7
|
Bertholet-Thomas A, Portefaix A, Flammier S, Dhelens C, Subtil F, Dubourg L, Laudy V, Le Bouar M, Boussaha I, Ndiaye M, Molin A, Lemoine S, Bacchetta J. Fluconazole in hypercalciuric patients with increased 1,25(OH) 2D levels: the prospective, randomized, placebo-controlled, double-blind FLUCOLITH trial. Trials 2022; 23:499. [PMID: 35710560 PMCID: PMC9204961 DOI: 10.1186/s13063-022-06302-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 04/13/2022] [Indexed: 11/23/2022] Open
Abstract
Background Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis possibly leading to chronic kidney disease (CKD) and bone complications in adults. Orphan diseases with different underlying primary pathophysiology share inappropriately increased 1,25(OH)2D levels and hypercalciuria, e.g., hypersensitivity to vitamin D and renal phosphate wasting. Their management is challenging, typically based on hyperhydration and dietary advice. The antifungal azoles are known to inhibit the 1α-hydroxylase and therefore decrease 1,25(OH)2D levels; they are commonly used, with well described pharmacokinetic and tolerability data. Fluconazole has been successfully reported to reduce calciuria in patients with CYP24A1 or SLC34A3 mutations, with no safety warnings. Thus, based on these case reports, we hypothesize that fluconazole is effective to decrease and normalize calciuria in patients with hypercalciuria and increased 1,25(OH)2D levels. Methods The FLUCOLITH trial is a prospective, interventional, randomized in parallel groups (1:1), placebo-controlled, double-blind trial. A total of 60 patients (10–60 years) with nephrolithiasis and/or nephrocalcinosis history, hypercalciuria (> 0.1 mmol/kg/day), increased 1,25(OH)2D levels (> 150 pmol/L), and 25-OH-D levels >20 nmol/L will be included. Inclusions will be performed only from mid-September to the beginning of February to avoid bias due to sunlight-induced vitamin D synthesis. The primary endpoint will be the proportion of patients with normalization of 24-h calciuria between baseline and 16 weeks, or with a relative decrease of at least 30% of 24-h calciuria in patients who still display at W16 a 24-h hypercalciuria. Discussion The current challenge is to propose an efficient treatment to patients with hypercalciuria and increased 1,25(OH)2D levels in order to prevent later complications and notably CKD that can ultimately lead to end-stage renal disease. Based on improvement of knowledge in phosphate/calcium metabolism, pathophysiology and genetics, the “off-label” use of fluconazole was recently reported to be useful in hypercalciuric patients with increased 1,25(OH)2D levels. Thus, the FLUCOLITH study is a unique opportunity to develop a new indication of a well-known and not expensive drug in orphan renal diseases, the ultimate objective being the secondary prevention of CKD worsening in these patients. Trial registration ClinicalTrials.gov NCT04495608. Registered on July 23, 2020. Supplementary Information The online version contains supplementary material available at 10.1186/s13063-022-06302-z.
Collapse
Affiliation(s)
- Aurélia Bertholet-Thomas
- Centre de Référence des Maladies Rénales Rares, filières maladies rares ORKID and ERK-Net, Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques, Hôpital Femme Mère Enfant, Boulevard Pinel, 69677, Bron, Cedex, France.,Centre de Référence des Maladies Rares du Calcium et du Phosphate, filière maladies rares OSCAR, Hôpital Femme Mère Enfant, Bron, France.,INSERM 1033, Prévention des Maladies Osseuses, Lyon, France
| | - Aurélie Portefaix
- Centre d'Investigation Clinique, Hôpital Cardiovasculaire Louis Pradel, Inserm 1407, 69500, Bron, France
| | - Sacha Flammier
- Centre de Référence des Maladies Rénales Rares, filières maladies rares ORKID and ERK-Net, Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques, Hôpital Femme Mère Enfant, Boulevard Pinel, 69677, Bron, Cedex, France.,Centre de Référence des Maladies Rares du Calcium et du Phosphate, filière maladies rares OSCAR, Hôpital Femme Mère Enfant, Bron, France
| | - Carole Dhelens
- Pharmacie, FRIPHARM, Hôpital Edouard Herriot, Lyon, France
| | - Fabien Subtil
- Service de Biostatistique, Hospices Civils de Lyon, Lyon, France.,Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Évolutive UMR 5558, Villeurbanne, France
| | - Laurence Dubourg
- Néphrologie, Dialyse, Hypertension Artérielle et Exploration Fonctionnelle Rénale, Hôpital Edouard Herriot, Lyon, France.,Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
| | - Valérie Laudy
- Centre d'Investigation Clinique, Hôpital Cardiovasculaire Louis Pradel, Inserm 1407, 69500, Bron, France
| | - Myrtille Le Bouar
- Centre d'Investigation Clinique, Hôpital Cardiovasculaire Louis Pradel, Inserm 1407, 69500, Bron, France
| | - Inesse Boussaha
- Centre d'Investigation Clinique, Hôpital Cardiovasculaire Louis Pradel, Inserm 1407, 69500, Bron, France
| | - Marietou Ndiaye
- Centre d'Investigation Clinique, Hôpital Cardiovasculaire Louis Pradel, Inserm 1407, 69500, Bron, France
| | - Arnaud Molin
- Service de Génétique, CHU de Caen, Caen, France.,Centre de Référence des Maladies Rares du Calcium et du Phosphate, filière maladies rares OSCAR Caen, Caen, France
| | - Sandrine Lemoine
- Centre de Référence des Maladies Rénales Rares, filières maladies rares ORKID and ERK-Net, Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques, Hôpital Femme Mère Enfant, Boulevard Pinel, 69677, Bron, Cedex, France.,Centre de Référence des Maladies Rares du Calcium et du Phosphate, filière maladies rares OSCAR, Hôpital Femme Mère Enfant, Bron, France.,Néphrologie, Dialyse, Hypertension Artérielle et Exploration Fonctionnelle Rénale, Hôpital Edouard Herriot, Lyon, France.,Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
| | - Justine Bacchetta
- Centre de Référence des Maladies Rénales Rares, filières maladies rares ORKID and ERK-Net, Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques, Hôpital Femme Mère Enfant, Boulevard Pinel, 69677, Bron, Cedex, France. .,Centre de Référence des Maladies Rares du Calcium et du Phosphate, filière maladies rares OSCAR, Hôpital Femme Mère Enfant, Bron, France. .,INSERM 1033, Prévention des Maladies Osseuses, Lyon, France. .,Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France.
| |
Collapse
|
8
|
Bacchetta J, Edouard T, Laverny G, Bernardor J, Bertholet-Thomas A, Castanet M, Garnier C, Gennero I, Harambat J, Lapillonne A, Molin A, Naud C, Salles JP, Laborie S, Tounian P, Linglart A. Vitamin D and calcium intakes in general pediatric populations: A French expert consensus paper. Arch Pediatr 2022; 29:312-325. [PMID: 35305879 DOI: 10.1016/j.arcped.2022.02.008] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 02/20/2022] [Indexed: 12/18/2022]
Abstract
OBJECTIVES Nutritional vitamin D supplements are often used in general pediatrics. Here, the aim is to address vitamin D supplementation and calcium nutritional intakes in newborns, infants, children, and adolescents to prevent vitamin D deficiency and rickets in general populations. STUDY DESIGN We formulated clinical questions relating to the following categories: the Patient (or Population) to whom the recommendation will apply; the Intervention being considered; the Comparison (which may be "no action," placebo, or an alternative intervention); and the Outcomes affected by the intervention (PICO). These PICO elements were arranged into the questions to be addressed in the literature searches. Each PICO question then formed the basis for a statement. The population covered consisted of children aged between 0 and 18 years and premature babies hospitalized in neonatology. Two groups were assembled: a core working group and a voting panel from different scientific pediatric committees from the French Society of Pediatrics and national scientific societies. RESULTS We present here 35 clinical practice points (CPPs) for the use of native vitamin D therapy (ergocalciferol, vitamin D2 and cholecalciferol, vitamin D3) and calcium nutritional intakes in general pediatric populations. CONCLUSION This consensus document was developed to provide guidance to health care professionals on the use of nutritional vitamin D and dietary modalities to achieve the recommended calcium intakes in general pediatric populations. These CPPs will be revised periodically. Research recommendations to study key vitamin D outcome measures in children are also suggested.
Collapse
Affiliation(s)
- J Bacchetta
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Filières Santé Maladies Rares OSCAR, ORKID et ERKNet, Hôpital Femme Mère Enfant, 59 Boulevard Pinel, Bron 69677 CEDEX, France; INSERM U1033, LYOS, Prévention des Maladies Osseuses, Lyon, France; Faculté de Médecine Lyon Est, Université de Lyon, Lyon, France.
| | - T Edouard
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Unité d'Endocrinologie, Génétique et Pathologies Osseuses, Filières Santé Maladies Rares OSCAR et BOND, Hôpital des Enfants, Toulouse, France
| | - G Laverny
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS UMR7104, INSERM U1258, Université de Strasbourg, Illkirch, France
| | - J Bernardor
- INSERM U1033, LYOS, Prévention des Maladies Osseuses, Lyon, France; Département de Pédiatrie, CHU de Nice, Nice, France
| | - A Bertholet-Thomas
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Filières Santé Maladies Rares OSCAR, ORKID et ERKNet, Hôpital Femme Mère Enfant, 59 Boulevard Pinel, Bron 69677 CEDEX, France; INSERM U1033, LYOS, Prévention des Maladies Osseuses, Lyon, France
| | - M Castanet
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Département de Pédiatrie, Filière Santé Maladies Rares OSCAR, CHU Rouen, Rouen, France
| | - C Garnier
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Filières Santé Maladies Rares OSCAR, ORKID et ERKNet, Hôpital Femme Mère Enfant, 59 Boulevard Pinel, Bron 69677 CEDEX, France
| | - I Gennero
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Unité d'Endocrinologie, Génétique et Pathologies Osseuses, Filières Santé Maladies Rares OSCAR et BOND, Hôpital des Enfants, Toulouse, France
| | - J Harambat
- Centre de Référence Maladies Rénales Rares, Unité de Néphrologie Pédiatrique, Hôpital Pellegrin-Enfants, Bordeaux, France; INSERM U1219, Bordeaux, France
| | - A Lapillonne
- Service de Pédiatrie et Réanimation Néonatales, EHU 7328 Université de Paris, Hôpital Necker- Enfants Malades, Paris, France; CNRC, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - A Molin
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Département de Génétique, Filière Santé Maladies Rares OSCAR, CHU Caen, Caen, France
| | - C Naud
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Filières Santé Maladies Rares OSCAR, ORKID et ERKNet, Hôpital Femme Mère Enfant, 59 Boulevard Pinel, Bron 69677 CEDEX, France
| | - J P Salles
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Unité d'Endocrinologie, Génétique et Pathologies Osseuses, Filières Santé Maladies Rares OSCAR et BOND, Hôpital des Enfants, Toulouse, France
| | - S Laborie
- Service de Réanimation Néonatale, Hôpital Femme Mère Enfant, Bron, France
| | - P Tounian
- Service de Nutrition et Gastroentérologie Pédiatriques, Hôpital Trousseau, Faculté de Médecine Sorbonne Université, Paris, France
| | - A Linglart
- AP-HP, Centre de Référence des Maladies Rares du Calcium et du Phosphore, Service d'Endocrinologie et diabète de l'enfant, Filières Santé Maladies Rares OSCAR, ERN endoRARE et BOND, Plateforme d'expertise des maladies rares Paris Saclay, Hôpital Bicêtre Paris-Saclay, Université Paris Saclay, INSERM U1185, Le Kremlin Bicêtre, France
| |
Collapse
|
9
|
Jordan P, Dorval G, Arrondel C, Morinière V, Tournant C, Audrezet MP, Michel-Calemard L, Putoux A, Lesca G, Labalme A, Whalen S, Loeuillet L, Martinovic J, Attie-Bitach T, Bessières B, Schaefer E, Scheidecker S, Lambert L, Beneteau C, Patat O, Boute-Benejean O, Molin A, Guimiot F, Fontanarosa N, Nizon M, Lefebvre M, Jeanpierre C, Saunier S, Heidet L. Targeted next-generation sequencing in a large series of fetuses with severe renal diseases. Hum Mutat 2022; 43:347-361. [PMID: 35005812 DOI: 10.1002/humu.24324] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 11/23/2021] [Accepted: 12/14/2021] [Indexed: 11/07/2022]
Abstract
We report the screening of a large panel of genes in a series of 100 fetuses (98 families) affected with severe renal defects. Causative variants were identified in 22% of cases, greatly improving genetic counseling. The percentage of variants explaining the phenotype was different according to the type of phenotype. The highest diagnostic yield was found in cases affected with the ciliopathy-like phenotype (11/15 families and, in addition, a single heterozygous or a homozygous Class 3 variant in PKHD1 in three unrelated cases with autosomal recessive polycystic kidney disease). The lowest diagnostic yield was observed in cases with congenital anomalies of the kidney and urinary tract (9/78 families and, in addition, Class 3 variants in GREB1L in three unrelated cases with bilateral renal agenesis). Inheritance was autosomal recessive in nine genes (PKHD1, NPHP3, CEP290, TMEM67, DNAJB11, FRAS1, ACE, AGT, and AGTR1), and autosomal dominant in six genes (PKD1, PKD2, PAX2, EYA1, BICC1, and MYOCD). Finally, we developed an original approach of next-generation sequencing targeted RNA sequencing using the custom capture panel used for the sequencing of DNA, to validate one MYOCD heterozygous splicing variant identified in two male siblings with megabladder and inherited from their healthy mother.
Collapse
Affiliation(s)
- Penelope Jordan
- APHP Service de Génétique, Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | - Guillaume Dorval
- APHP Service de Génétique, Hôpital Universitaire Necker-Enfants Malades, Paris, France.,Inserm U1163, Laboratoire des Maladies Rénales Héréditaires Institut Imagine, Université de Paris, Paris, France.,APHP Service de Néphrologie Pédiatrique, Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | - Christelle Arrondel
- Inserm U1163, Laboratoire des Maladies Rénales Héréditaires Institut Imagine, Université de Paris, Paris, France
| | - Vincent Morinière
- APHP Service de Génétique, Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | - Carole Tournant
- APHP Service de Génétique, Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | - Marie-Pierre Audrezet
- Service de Génétique moléculaire, Génétique, Génomique et Biotechnologies, UMR 1078, Hôpital Universitaire de Brest, Brest, France
| | - Laurence Michel-Calemard
- Service Biochimie Biologie Moléculaire Grand Est, Hospices Civils de Lyon, Groupement Hospitalier Est, CBPE, Bron, France
| | - Audrey Putoux
- Service de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
| | - Gaethan Lesca
- Service de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
| | - Audrey Labalme
- Service de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
| | - Sandra Whalen
- APHP UF de Génétique Clinique, Centre de Référence des Anomalies du Développement et Syndromes Malformatifs, APHP, Hôpital Armand Trousseau, ERN ITHACA, Sorbonne Université, Paris, France
| | - Laurence Loeuillet
- APHP Service d'Embryofœtopathologie, Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | - Jelena Martinovic
- APHP Service de Fœtopathologie, Hôpital Universitaire Antoine Béclère, Clamart, France
| | - Tania Attie-Bitach
- APHP Service d'Embryofœtopathologie, Hôpital Universitaire Necker-Enfants Malades, Paris, France.,Inserm U 1163, Institut Imagine, Université de Paris, Paris, France
| | - Bettina Bessières
- APHP Service d'Embryofœtopathologie, Hôpital Universitaire Necker-Enfants Malades, Paris, France.,Inserm U 1163, Institut Imagine, Université de Paris, Paris, France
| | - Elise Schaefer
- Service de Génétique Médicale, Institut de Génétique médicale d'Alsace, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Sophie Scheidecker
- Service de Génétique Médicale, Institut de Génétique médicale d'Alsace, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Laetitia Lambert
- Service de Génétique Médicale, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France
| | - Claire Beneteau
- Service de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Olivier Patat
- Service de Génétique Médicale, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Odile Boute-Benejean
- Service de Génétique Médicale, Hôpital Jeanne de Flandre, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Arnaud Molin
- Service de Génétique Médicale, Centre Hospitalier Universitaire de Caen, Caen, France
| | - Fabien Guimiot
- APHP Service d'Embryo-Fœtopathologie, Hôpital Universitaire Robert Debré, Paris, France
| | | | - Mathilde Nizon
- Service de Génétique Médicale, CHU Nantes, L'institut Du Thorax, INSERM, CNRS, UNIV Nantes, Nantes, France
| | - Mathilde Lefebvre
- APHP Service de Pathologie fœtale, Hôpital Universitaire Armand Trousseau, Paris, France
| | - Cécile Jeanpierre
- Inserm U1163, Laboratoire des Maladies Rénales Héréditaires Institut Imagine, Université de Paris, Paris, France
| | - Sophie Saunier
- Inserm U1163, Laboratoire des Maladies Rénales Héréditaires Institut Imagine, Université de Paris, Paris, France
| | - Laurence Heidet
- Inserm U1163, Laboratoire des Maladies Rénales Héréditaires Institut Imagine, Université de Paris, Paris, France.,APHP Service de Néphrologie Pédiatrique, Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Hôpital Universitaire Necker-Enfants Malades, Paris, France
| |
Collapse
|
10
|
Kaufmann M, Schlingmann KP, Berezin L, Molin A, Sheftel J, Vig M, Gallagher JC, Nagata A, Masoud SS, Sakamoto R, Nagasawa K, Uesugi M, Kottler ML, Konrad M, Jones G. Differential diagnosis of vitamin D-related hypercalcemia using serum vitamin D metabolite profiling. J Bone Miner Res 2021; 36:1340-1350. [PMID: 33856702 DOI: 10.1002/jbmr.4306] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 03/26/2021] [Accepted: 04/08/2021] [Indexed: 11/10/2022]
Abstract
Genetic causes of vitamin D-related hypercalcemia are known to involve mutation of 25-hydroxyvitamin D-24-hydroxylase CYP24A1 or the sodium phosphate co-transporter SLC34A1, which result in excessive 1,25-(OH)2 D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases remain unresolved. In this case-control study, we used precision vitamin D metabolite profiling based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) of an expanded range of vitamin D metabolites to screen German and French cohorts of hypercalcemia patients, to identify patients with altered vitamin D metabolism where involvement of CYP24A1 or SLC34A1 mutation had been ruled out and who possessed normal 25-OH-D3 :24,25-(OH)2 D3 ratios. Profiles were compared to those of hypercalcemia patients with hypervitaminosis D, Williams-Beuren syndrome (WBS), CYP24A1 mutation, and normal subjects with a range of 25-OH-D levels. We observed that certain IH and WBS patients exhibited a unique profile comprising eightfold to 10-fold higher serum 23,25,26-(OH)3 D3 and 25-OH-D3 -26,23-lactone than normals, as well as very low serum 1,25-(OH)2 D3 (2-5 pg/ml) and elevated 1,24,25-(OH)3 D3 , which we interpret implies hypersensitive expression of vitamin D-dependent genes, including CYP24A1, as a general underlying mechanism of hypercalcemia in these patients. Because serum 25-OH-D3 and 24,25-(OH)2 D3 remained normal, we excluded the possibility that the aberrant profile was caused by hypervitaminosis D, but instead points to an underlying genetic cause that parallels the effect of Williams syndrome transcription factor deficiency in WBS. Furthermore, we observed normalization of serum calcium and vitamin D metabolite profiles at follow-up of an IH patient where 25-OH-D was reduced to 9 ng/ml, suggesting that symptomatic IH may depend on vitamin D nutritional status. Other hypercalcemic patients with complex conditions exhibited distinct vitamin D metabolite profiles. Our work points to the importance of serum vitamin D metabolite profiling in the differential diagnosis of vitamin D-related hypercalcemia that can rationalize expensive genetic testing, and assist healthcare providers in selecting appropriate treatment. © 2021 American Society for Bone and Mineral Research (ASBMR).
Collapse
Affiliation(s)
- Martin Kaufmann
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.,Department of Surgery, Queen's University, Kingston, Ontario, Canada
| | | | - Linor Berezin
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada
| | - Arnaud Molin
- Department of Genetics University Hospital, Caen-Normandie University, Caen, France
| | - Jesse Sheftel
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada
| | - Melanie Vig
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada
| | - John C Gallagher
- Bone Metabolism Unit, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USA
| | - Akiko Nagata
- Department of Biotechnology and Life Sciences, Faculty of Technology, Tokyo University of Technology and Agriculture, Tokyo, Japan
| | - Shadi Sedghi Masoud
- Department of Biotechnology and Life Sciences, Faculty of Technology, Tokyo University of Technology and Agriculture, Tokyo, Japan
| | - Ryota Sakamoto
- Department of Biotechnology and Life Sciences, Faculty of Technology, Tokyo University of Technology and Agriculture, Tokyo, Japan
| | - Kazuo Nagasawa
- Department of Biotechnology and Life Sciences, Faculty of Technology, Tokyo University of Technology and Agriculture, Tokyo, Japan
| | - Motonari Uesugi
- Institute for Integrated Cell-Material Sciences and Institute for Chemical Research, Kyoto University Kyoto University, Kyoto, Japan
| | - Marie Laure Kottler
- Department of Genetics University Hospital, Caen-Normandie University, Caen, France
| | - Martin Konrad
- Department of General Pediatrics, University Children's Hospital, Munster, Germany
| | - Glenville Jones
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada
| |
Collapse
|
11
|
Apetrei A, Molin A, Gruchy N, Godin M, Bracquemart C, Resbeut A, Rey G, Nadeau G, Richard N. A novel synonymous variant in exon 1 of GNAS gene results in a cryptic splice site and causes pseudohypoparathyroidism type 1A and pseudo-pseudohypoparathyroidism in a French family. Bone Rep 2021; 14:101073. [PMID: 33997150 PMCID: PMC8100090 DOI: 10.1016/j.bonr.2021.101073] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Revised: 04/17/2021] [Accepted: 04/20/2021] [Indexed: 12/31/2022] Open
Abstract
INTRODUCTION Pseudohypoparathyroidism type 1A (PHP1A) and pseudopseudohypoparathyroidism (PPHP) (Inactivating PTH/PTHrP Signaling Disorders type 2, IPPSD2) are two rare autosomal disorders caused by loss-of-function mutations on either maternal or paternal allele, respectively, in the imprinted GNAS gene, which encodes the α subunit of the ubiquitously-expressed stimulatory G protein (Gαs). CASE PRESENTATION We investigated a synonymous GNAS variant NM_001077488.2: c.108C>A / p.(Val36=) identified in a family presenting with IPPSD2 phenotype. In silico splicing prediction algorithms were in favor of a deleterious effect of this variant, by creating a new donor splicing site. The GNAS expression studies in blood suggested haploinsufficiency and showed an alternate splice product demonstrating the unmasking of a cryptic site, leading to a 34 base pairs deletion and the creation of a probable unstable RNA.We present the first familial case of IPPSD2 caused by a pathogenic synonymous variant in GNAS gene.
Collapse
Affiliation(s)
- Andreea Apetrei
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, Reference Center of Rare Diseases of Calcium and Phosphorus Metabolism, EA 7450 BioTARGen, Caen, France
| | - Arnaud Molin
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, Reference Center of Rare Diseases of Calcium and Phosphorus Metabolism, EA 7450 BioTARGen, Caen, France
| | - Nicolas Gruchy
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, Reference Center of Rare Diseases of Calcium and Phosphorus Metabolism, EA 7450 BioTARGen, Caen, France
| | - Manon Godin
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, Reference Center of Rare Diseases of Calcium and Phosphorus Metabolism, EA 7450 BioTARGen, Caen, France
| | - Claire Bracquemart
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, Reference Center of Rare Diseases of Calcium and Phosphorus Metabolism, EA 7450 BioTARGen, Caen, France
| | - Antoine Resbeut
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, Reference Center of Rare Diseases of Calcium and Phosphorus Metabolism, EA 7450 BioTARGen, Caen, France
| | - Gaëlle Rey
- Metropole Savoie Hospital Center, Genetics Department, Chambéry, France
| | - Gwenaël Nadeau
- Metropole Savoie Hospital Center, Genetics Department, Chambéry, France
| | - Nicolas Richard
- Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, Reference Center of Rare Diseases of Calcium and Phosphorus Metabolism, EA 7450 BioTARGen, Caen, France
| |
Collapse
|
12
|
Bernardor J, Flammier S, Cabet S, Lemoine S, Chapurlat R, Molin A, Bertholet-Thomas A, Bacchetta J. Intermittent Bi-Daily Sub-cutaneous Teriparatide Administration in Children With Hypoparathyroidism: A Single-Center Experience. Front Pediatr 2021; 9:764040. [PMID: 34820344 PMCID: PMC8606674 DOI: 10.3389/fped.2021.764040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 10/18/2021] [Indexed: 11/13/2022] Open
Abstract
Introduction: The use of teriparatide has been reported in children with hypoparathyroidism as an investigational physiologic replacement therapy. Methods: We aimed to retrospectively report our pediatric experience of bi-daily sub-cutaneous teriparatide. Results are presented as median (25th-75th quartile). As part of the routine follow-up of these patients with hypoparathyroidism, total calcium at H0 (i.e., just before injection) and H4 (i.e., 4 h after teriparatide injection) and other biomarker parameters were regularly assessed. Results: At a median age of 10.7 (8.1-12.6) years, an estimated glomerular filtration rate (eGFR) of 110 (95-118) mL/min/1.73 m2, calcium levels of 1.87 (1.81-1.96) mmol/L and an age-standardized phosphate of 3.8 (2.5-4.9) SDS, teriparatide therapy was introduced in 10 patients at the dose of 1.1 (0.7-1.5) μg/kg/day (20 μg twice daily), with further adjustment depending on calcium levels. Six patients already displayed nephrocalcinosis. Severe side effects were reported in one child: two episodes of symptomatic hypocalcemia and one of iatrogenic hypercalcemia; one teenager displayed dysgueusia. Calcium levels at H0 did not significantly increase whilst calcium at H4 and phosphate levels significantly increased and decreased, respectively. After 12 months, eGFR, calcium and age-standardized phosphate levels were 108 (90-122) mL/min/1.73 m2, 2.36 (2.23-2.48) mmol/L, 0.5 (-0.1 to 1.5), and 68 (63-74) nmol/L, respectively, with a significant decrease in phosphate levels (p = 0.01). Urinary calcium and calcium/creatinine ratio remained stable; no nephrolithiasis was observed but two moderate nephrocalcinosis appeared. Conclusion: Intermittent teriparatide therapy significantly improves calcium and phosphate control, without increasing calciuria. It appears to be safe and well-tolerated in children.
Collapse
Affiliation(s)
- Julie Bernardor
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Centre de Référence des Maladies Rénales Rares, Filières de Santé Maladies Rares OSCAR, ORKID et ERKNet, Service de Néphrologie Rhumatologie et Dermatologie Pédiatriques, Hôpital Femme Mère Enfant, Bron, France.,INSERM UMR S1033 Research Unit, Lyon, France.,Service de Néphrologie Pédiatrique, CHU de Nice, Hôpital Archet, Nice, France.,Faculté de Médecine, Université Côte d'Azur, Nice, France
| | - Sacha Flammier
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Centre de Référence des Maladies Rénales Rares, Filières de Santé Maladies Rares OSCAR, ORKID et ERKNet, Service de Néphrologie Rhumatologie et Dermatologie Pédiatriques, Hôpital Femme Mère Enfant, Bron, France
| | - Sara Cabet
- Département de Radiologie Pédiatrique et Fœtale, Hôpital Femme Mère Enfant, Lyon, France
| | - Sandrine Lemoine
- Service d'Exploration Fonctionnelle Rénale, Centre de Référence des Maladies Rares du Calcium et du Phosphore, Centre de Référence des Maladies Rénales Rares, Filières de Santé Maladies Rares OSCAR et ORKID, Département de Néphrologie, Hôpital Edouard Herriot, Lyon, France.,Faculté de Médecine Lyon Est, Université de Lyon, Lyon, France
| | - Roland Chapurlat
- INSERM UMR S1033 Research Unit, Lyon, France.,Faculté de Médecine Lyon Est, Université de Lyon, Lyon, France.,Service de Rhumatologie, Hôpital Edouard Herriot, Lyon, France
| | - Arnaud Molin
- Université de Normandie, UNICAEN, Unité de génétique, EA7450 BioTARGen, CHU de Caen Normandie, Caen, France
| | - Aurélia Bertholet-Thomas
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Centre de Référence des Maladies Rénales Rares, Filières de Santé Maladies Rares OSCAR, ORKID et ERKNet, Service de Néphrologie Rhumatologie et Dermatologie Pédiatriques, Hôpital Femme Mère Enfant, Bron, France
| | - Justine Bacchetta
- Centre de Référence des Maladies Rares du Calcium et du Phosphore, Centre de Référence des Maladies Rénales Rares, Filières de Santé Maladies Rares OSCAR, ORKID et ERKNet, Service de Néphrologie Rhumatologie et Dermatologie Pédiatriques, Hôpital Femme Mère Enfant, Bron, France.,INSERM UMR S1033 Research Unit, Lyon, France.,Faculté de Médecine Lyon Est, Université de Lyon, Lyon, France
| |
Collapse
|
13
|
Molin A, Lemoine S, Kaufmann M, Breton P, Nowoczyn M, Ballandonne C, Coudray N, Mittre H, Richard N, Ryckwaert A, Lavillaureix A, Jones G, Bacchetta J, Kottler ML. Overlapping Phenotypes Associated With CYP24A1, SLC34A1, and SLC34A3 Mutations: A Cohort Study of Patients With Hypersensitivity to Vitamin D. Front Endocrinol (Lausanne) 2021; 12:736240. [PMID: 34721296 PMCID: PMC8548709 DOI: 10.3389/fendo.2021.736240] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2021] [Accepted: 09/07/2021] [Indexed: 12/14/2022] Open
Abstract
Mutations in CYP24A1 (vitamin D 24-hydroxylase) and SLC34A1 (renal phosphate transporter NPT2a) cause autosomal recessive Infantile Hypercalcemia type 1 and 2, illustrating links between vitamin D and phosphate metabolism. Patients may present with hypercalciuria and alternate between chronic phases with normal serum calcium but inappropriately high 1,25-(OH)2D and appropriately low PTH, and acute phases with hypercalcemia with suppressed PTH. Mutations in SLC34A3 and SLC9A3R1 have been associated with phosphate wasting without hypercalcemia. The aims of this study were to evaluate the frequency of mutations in these genes in patients with a medical history suggestive of CYP24A1 mutation to search for a specific pattern. Using next generation sequencing, we screened for mutations in 185 patients with PTH levels < 20 pg/mL, hypercalcemia and/or hypercalciuria, and relatives. Twenty-eight (15%) patients harbored biallelic mutations in CYP24A1 (25) and SLC34A3 (3), mostly associated with renal disease (lithiasis, nephrocalcinosis) (86%). Hypophosphatemia was found in 7 patients with biallelic mutations in CYP24A1 and a normal phosphatemia was reported in 2 patients with biallelic mutations in SLC34A3. Rare variations in SLC34A1 and SLC34A3 were mostly of uncertain significance. Fifteen patients (8%) carried only one heterozygous mutation. Heterozygous relatives carrying SLC34A1 or SLC34A3 variation may present with biochemical changes in mineral metabolism. Two patients' genotype may suggest digenism (heterozygous variations in different genes). No variation was found in SLC9A3R1. As no specific pattern can be found, patients with medical history suggestive of CYP24A1 mutation should benefit from SLC34A1 and SLC34A3 analysis.
Collapse
Affiliation(s)
- Arnaud Molin
- Caen University Hospital, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (OSCAR), Caen, France
- Caen Normandy University, Medical School, Caen, France
- BioTARGEN, Caen Normandy University, Caen, France
- OeReCa, Caen Normandy University, Caen, France
- *Correspondence: Arnaud Molin,
| | - Sandrine Lemoine
- Department of Nephrology and Renal Functional Explorations, Edouard Herriot Hospital, Lyon, France
- University of Lyon, University of Lyon 1, Villeurbanne, France
| | - Martin Kaufmann
- Queen’s University, Department of Biomedical and Molecular Sciences, Kingston, ON, Canada
| | - Pierre Breton
- Caen University Hospital, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (OSCAR), Caen, France
| | - Marie Nowoczyn
- Caen Normandy University, Medical School, Caen, France
- Caen University Hospital, Department of Biochemistry, Caen, France
| | | | - Nadia Coudray
- Caen University Hospital, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (OSCAR), Caen, France
| | - Hervé Mittre
- Caen University Hospital, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (OSCAR), Caen, France
- Caen Normandy University, Medical School, Caen, France
- OeReCa, Caen Normandy University, Caen, France
| | - Nicolas Richard
- Caen University Hospital, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (OSCAR), Caen, France
- BioTARGEN, Caen Normandy University, Caen, France
| | - Amélie Ryckwaert
- Department of Pediatrics, Rennes University Hospital, Rennes, France
| | | | - Glenville Jones
- Queen’s University, Department of Biomedical and Molecular Sciences, Kingston, ON, Canada
| | - Justine Bacchetta
- University of Lyon, University of Lyon 1, Villeurbanne, France
- Reference Center for Rare Kidney Diseases (ORKID), Department of Pediatric Nephrology, Rhumatology and Dermatology, Woman Mother Children Hospital, Bron, France
- Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (OSCAR), Department of Pediatric Nephrology, Rhumatology and Dermatology, Woman Mother Children Hospital, Bron, France
- INSERM 1033, Bone Diseases Prevention, Lyon, France
| | - Marie-Laure Kottler
- Caen University Hospital, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (OSCAR), Caen, France
- Caen Normandy University, Medical School, Caen, France
- BioTARGEN, Caen Normandy University, Caen, France
| |
Collapse
|
14
|
Rovito D, Belorusova AY, Chalhoub S, Rerra AI, Guiot E, Molin A, Linglart A, Rochel N, Laverny G, Metzger D. Cytosolic sequestration of the vitamin D receptor as a therapeutic option for vitamin D-induced hypercalcemia. Nat Commun 2020; 11:6249. [PMID: 33288743 PMCID: PMC7721737 DOI: 10.1038/s41467-020-20069-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Accepted: 11/12/2020] [Indexed: 11/09/2022] Open
Abstract
The bioactive vitamin D3, 1α,25(OH)2D3, plays a central role in calcium homeostasis by controlling the activity of the vitamin D receptor (VDR) in various tissues. Hypercalcemia secondary to high circulating levels of vitamin D3 leads to hypercalciuria, nephrocalcinosis and renal dysfunctions. Current therapeutic strategies aim at limiting calcium intake, absorption and resorption, or 1α,25(OH)2D3 synthesis, but are poorly efficient. In this study, we identify WBP4 as a new VDR interactant, and demonstrate that it controls VDR subcellular localization. Moreover, we show that the vitamin D analogue ZK168281 enhances the interaction between VDR and WBP4 in the cytosol, and normalizes the expression of VDR target genes and serum calcium levels in 1α,25(OH)2D3-intoxicated mice. As ZK168281 also blunts 1α,25(OH)2D3-induced VDR signaling in fibroblasts of a patient with impaired vitamin D degradation, this VDR antagonist represents a promising therapeutic option for 1α,25(OH)2D3-induced hypercalcemia. Current therapeutic strategies for vitamin D-induced hypercalcemia are poorly efficient. Here the authors identify a new interaction between the vitamin D receptor (VDR) and WBP4 controlling the subcellular localization of VDR and show that ZK168281, a VDR antagonist, enhances the interaction between VDR and WBP4 blunting VDR signalling and normalizing calcium levels in vitamin D-intoxicated mice.
Collapse
Affiliation(s)
- Daniela Rovito
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.,Centre National de la Recherche Scientifique, UMR7104, Illkirch, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Illkirch, France.,Université de Strasbourg, Illkirch, France
| | - Anna Y Belorusova
- Medicinal Chemistry, Respiratory, Inflammation and Autoimmunity, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Sandra Chalhoub
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.,Centre National de la Recherche Scientifique, UMR7104, Illkirch, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Illkirch, France.,Université de Strasbourg, Illkirch, France
| | - Anna-Isavella Rerra
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.,Centre National de la Recherche Scientifique, UMR7104, Illkirch, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Illkirch, France.,Université de Strasbourg, Illkirch, France
| | - Elvire Guiot
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.,Centre National de la Recherche Scientifique, UMR7104, Illkirch, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Illkirch, France.,Université de Strasbourg, Illkirch, France
| | - Arnaud Molin
- Université de Normandie, UNICAEN, CHU de Caen Normandie, Service de Génétique, EA 7450 BIOTARGEN, Caen, France.,Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (OSCAR), Paris, France
| | - Agnès Linglart
- Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (OSCAR), Paris, France.,Université de Paris Saclay, AP-HP, Hôpital Bicêtre, DMU SEA, INSERM, U1185, Le Kremlin Bicêtre, France
| | - Natacha Rochel
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.,Centre National de la Recherche Scientifique, UMR7104, Illkirch, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Illkirch, France.,Université de Strasbourg, Illkirch, France
| | - Gilles Laverny
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France. .,Centre National de la Recherche Scientifique, UMR7104, Illkirch, France. .,Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Illkirch, France. .,Université de Strasbourg, Illkirch, France.
| | - Daniel Metzger
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France. .,Centre National de la Recherche Scientifique, UMR7104, Illkirch, France. .,Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Illkirch, France. .,Université de Strasbourg, Illkirch, France.
| |
Collapse
|
15
|
Billon C, Molin A, Poirsier C, Clemenson A, Dauge C, Grelet M, Sigaudy S, Patrier S, Goldenberg A, Layet V, Tantau J, Fleury C, Liard A, Diguet A, Fritih R, Verspyck E, Rendu J, Boutaud L, Tessier A, Thomas S, Razavi F, Achaiaa A, Elkhartoufi N, Hakkakian L, Magnin E, Bôle-Feysot C, Masson C, Ville Y, Roth P, Prieur F, Bessieres B, Bonniere M, Attie-Bitach T. Fetal megacystis-microcolon: Genetic mutational spectrum and identification of PDCL3 as a novel candidate gene. Clin Genet 2020; 98:261-273. [PMID: 32621347 DOI: 10.1111/cge.13801] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 06/24/2020] [Accepted: 06/25/2020] [Indexed: 12/13/2022]
Abstract
Megacystis-microcolon-intestinal-hypoperistalsis syndrome (MMIHS) is a severe congenital visceral myopathy characterized by an abdominal distension due to a large non-obstructed urinary bladder, a microcolon and intestinal hypo- or aperistalsis. Most of the patients described to date carry a sporadic heterozygous variant in ACTG2. More recently, recessive forms have been reported and mutations in MYH11, LMOD1, MYLK and MYL9 have been described at the molecular level. In the present report, we describe five patients carrying a recurrent heterozygous variant in ACTG2. Exome sequencing performed in four families allowed us to identify the genetic cause in three. In two families, we identified variants in MMIHS causal genes, respectively a nonsense homozygous variant in MYH11 and a previously described homozygous deletion in MYL9. Finally, we identified compound heterozygous variants in a novel candidate gene, PDCL3, c.[143_144del];[380G>A], p.[(Tyr48Ter)];[(Cys127Tyr)]. After cDNA analysis, a complete absence of PDLC3 expression was observed in affected individuals, indicating that both mutated transcripts were unstable and prone to mediated mRNA decay. PDCL3 encodes a protein involved in the folding of actin, a key step in thin filament formation. Presumably, loss-of-function of this protein affects the contractility of smooth muscle tissues, making PDCL3 an excellent candidate gene for autosomal recessive forms of MMIHS.
Collapse
Affiliation(s)
- Clarisse Billon
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France.,Département de Génétique, Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - Arnaud Molin
- Département de Génétique, Normandie Université, UNICAEN, CHU de Caen Normandie, Caen, France
| | | | - Alix Clemenson
- Service d'Anatomie et Cytotologie Pathologique, CHU de Saint Etienne, Saint Etienne, France
| | - Coralie Dauge
- Department of Pathology, University Hospital, Caen, France
| | - Maude Grelet
- Département de Génétique Médicale, Hôpital de la Timone, APHM, Marseille, France
| | - Sabine Sigaudy
- Département de Génétique Médicale, Hôpital de la Timone, APHM, Marseille, France
| | - Sophie Patrier
- Service d'Anatomie Pathologique, CHU Ch. Nicolle, Rouen, France
| | - Alice Goldenberg
- centre de référence anomalies du développement et syndromes malformatifs, CHU de Rouen, Centre Normand de Génomique et de Médecine Personnalisée, France
| | - Valérie Layet
- Consultations de génétique, Groupe Hospitalier du Havre, Le Havre, France
| | - Julia Tantau
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Clémence Fleury
- Department of Pathology, Robert-Debré University Hospital, Reims, France
| | - Agnès Liard
- Département de chirurgie infantile, Chu de Rouen, Rouen, France
| | - Alain Diguet
- Laboratoire d'anatomie pathologique, pavillon Jacques-Delarue, CHU de Rouen, Rouen, France
| | - Radia Fritih
- Pathology Department, Hôpital de la Timone, APHM, Marseille, France
| | - Eric Verspyck
- Department of Obstetrics and Gynecology, Rouen University Hospital, Rouen, France
| | - John Rendu
- Unité Médicale de Génétique Moléculaire, Inserm U1216, CHU de Grenoble, Grenoble, France
| | - Lucile Boutaud
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France.,INSERM UMR 1163, Université de Paris, Imagine Institute, Paris, France
| | - Aude Tessier
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Sophie Thomas
- INSERM UMR 1163, Université de Paris, Imagine Institute, Paris, France
| | - Ferechté Razavi
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Amale Achaiaa
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Nadia Elkhartoufi
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Leila Hakkakian
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Eglantine Magnin
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | | | - Cécile Masson
- Bioinformatics Platform, INSERM UMR 1163, Institut Imagine, Paris, France
| | - Yves Ville
- Service d'Obstétrique, Maternité, Chirurgie, Médecine et Imagerie Fœtales, Hôpital Necker-Enfants Malades, AP-HP, Centre - Université de Paris, Paris, France
| | - Philippe Roth
- Service d'Obstétrique, Maternité, Chirurgie, Médecine et Imagerie Fœtales, Hôpital Necker-Enfants Malades, AP-HP, Centre - Université de Paris, Paris, France
| | - Fabienne Prieur
- Service de génétique, Hôpital Nord CHU Saint-Etienne, Saint Etienne, France
| | - Bettina Bessieres
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Maryse Bonniere
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Tania Attie-Bitach
- Service d'Histologie-Embryologie-Cytogénétique, Unité d'Embryofoetopathologie, Hôpital Necker-Enfants Malades, APHP, Paris, France.,INSERM UMR 1163, Université de Paris, Imagine Institute, Paris, France
| |
Collapse
|
16
|
Wiedemann A, Renard E, Molin A, Weryha G, Oussalah A, Guéant JL, Feillet F. Prolonged 25-OH Vitamin D Deficiency Does Not Impair Bone Mineral Density in Adult Patients With Vitamin D 25-Hydroxylase Deficiency (CYP2R1). Calcif Tissue Int 2020; 107:191-194. [PMID: 32430692 DOI: 10.1007/s00223-020-00704-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Accepted: 05/12/2020] [Indexed: 12/30/2022]
Abstract
Vitamin D-dependent rickets type 1B (VDDR1B) is an autosomal semidominant genetic disorder caused by a deficiency in CYP2R1, which encodes vitamin D 25-hydroxylase, an enzyme that plays a crucial role in the conversion of vitamin D to 25-dihydroxyvitamin D3. VDDR1B is a severe form of rickets that occurs during infancy and which is responsive to 25-OH vitamin D supplementation. We studied three adult patients from a multi-consanguineous family with VDDR1B. They have been diagnosed with pseudo-nutritional rickets and treated during their adolescence with 25-OH vitamin D. These patients stopped their treatments at the end of adolescence and were contacted 14 to 17 years later when VDDR1B diagnosis was carried out in their niece and nephews. These three patients had undetectable 25-OH vitamin D, but normal levels of plasma 1-25(OH)2 vitamin D. All patients had a hip bone mineral density and a normal vertebral despite osteoarthritis degenerative lesions which may impact BMD evaluation. These findings show that vitamin D supplementation has a questionable effect, if any, for osteoporosis prevention in adulthood in contrast to its crucial importance during infancy and adolescence.
Collapse
Affiliation(s)
- Arnaud Wiedemann
- Reference Center for Inborn Errors of Metabolism, Pediatric Unit, University Hospital of Nancy, Nancy, France.
- INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, University of Lorraine, Nancy, France.
| | - Emeline Renard
- Reference Center for Inborn Errors of Metabolism, Pediatric Unit, University Hospital of Nancy, Nancy, France
| | - Arnaud Molin
- Department of Genetics, University Hospital of Caen, Caen, France
| | - Georges Weryha
- Department of Endocrinology Unit, University Hospital of Nancy, Nancy, France
| | - Abderrahim Oussalah
- INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, University of Lorraine, Nancy, France
- Division of Biochemistry, Molecular Biology, Nutrition, and Metabolism, Department of Molecular Medicine, University Hospital of Nancy, Nancy, France
| | - Jean-Louis Guéant
- INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, University of Lorraine, Nancy, France
- Division of Biochemistry, Molecular Biology, Nutrition, and Metabolism, Department of Molecular Medicine, University Hospital of Nancy, Nancy, France
| | - François Feillet
- Reference Center for Inborn Errors of Metabolism, Pediatric Unit, University Hospital of Nancy, Nancy, France
- INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, University of Lorraine, Nancy, France
| |
Collapse
|
17
|
Jourdan-Voyen L, Touraine R, Masutti JP, Busa T, Vincent-Delorme C, Dreyfus L, Molin A, Savey B, Mounzer A, Assaf Z, Atallah V, da Cruz V, Gaillard D, Leroy-Terquem E, Mouton JB, Ghoumid J, Picaud JC, Dijoud F, Bouquillon S, Baumann C, Lambert L. Phenotypic and genetic spectrum of alveolar capillary dysplasia: a retrospective cohort study. Arch Dis Child Fetal Neonatal Ed 2020; 105:387-392. [PMID: 31641027 DOI: 10.1136/archdischild-2019-317121] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Revised: 09/19/2019] [Accepted: 09/28/2019] [Indexed: 12/29/2022]
Abstract
OBJECTIVE Alveolar capillary dysplasia (ACD) is one of the causes of pulmonary hypertension. Its diagnosis is histological but new pathogenetic data have emerged. The aim of this study was to describe a French cohort of patients with ACD to improve the comprehension and the diagnosis of this pathology which is probably underdiagnosed. METHODS A retrospective observational study was conducted in French hospitals. Patients born between 2005 and 2017, whose biological samples were sent to the French genetic reference centres, were included. Clinical, histological and genetic data were retrospectively collected. RESULTS We presented a series of 21 patients. The mean of postmenstrual age at birth was 37.6 weeks. The first symptoms appeared on the median of 2.5 hours. Pulmonary hypertension was diagnosed in 20 patients out of 21. Two cases had prolonged survival (3.3 and 14 months). Histological analysis was done on lung tissue from autopsy (57.1% of cases) or from percutaneous biopsy (28.6%). FOXF1 was found abnormal in 15 patients (71.4%): 8 deletions and 7 point mutations. Two deletions were found by chromosomal microarray. CONCLUSION This study is one of the largest clinically described series in literature. It seems crucial to integrate genetics early into diagnostic support. We propose a diagnostic algorithm for helping medical teams to improve diagnosis of this pathology.
Collapse
Affiliation(s)
| | | | | | - Tiffany Busa
- Medical Genetics, Hôpital de la Timone, Marseille, France
| | | | | | | | | | | | - Ziad Assaf
- Neonatology, Hopital Universitaire Necker-Enfants Malades, Paris, France
| | | | | | | | | | | | - Jamal Ghoumid
- Genetics, CHRU Lille Pôle Spécialités Médico-Chirurgicales, Arras, France
| | - Jean-Charles Picaud
- Neonatology, Hopital Croix Rousse, Lyon, France.,Neonatology, Universite Lyon 1 Faculte de Medecine et de Maieutique Lyon-Sud Charles Merieux, Oullins, France
| | | | - Sonia Bouquillon
- Cytogenetics, CHRU Lille Pôle Spécialités Médico-Chirurgicales, Arras, France
| | - Cédric Baumann
- Platform of Clinical Research Facility PARC, CHU Nancy, Nancy, France
| | | |
Collapse
|
18
|
Snanoudj S, Molin A, Colson C, Coudray N, Paulien S, Mittre H, Gérard M, Schaefer E, Goldenberg A, Bacchetta J, Odent S, Naudion S, Demeer B, Faivre L, Gruchy N, Kottler ML, Richard N. Maternal Transmission Ratio Distortion of GNAS Loss-of-Function Mutations. J Bone Miner Res 2020; 35:913-919. [PMID: 31886927 DOI: 10.1002/jbmr.3948] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Revised: 12/09/2019] [Accepted: 12/14/2019] [Indexed: 12/14/2022]
Abstract
Pseudohypoparathyroidism type 1A (PHP1A) and pseudopseudohypoparathyroidism (PPHP) are two rare autosomal dominant disorders caused by loss-of-function mutations in the imprinted Guanine Nucleotide Binding Protein, Alpha Stimulating Activity (GNAS) gene, coding Gs α. PHP1A is caused by mutations in the maternal allele and results in Albright's hereditary osteodystrophy (AHO) and hormonal resistance, mainly to the parathormone (PTH), whereas PPHP, with AHO features and no hormonal resistance, is linked to mutations in the paternal allele. This study sought to investigate parental transmission of GNAS mutations. We conducted a retrospective study in a population of 204 families with 361 patients harboring GNAS mutations. To prevent ascertainment bias toward a higher proportion of affected children due to the way in which data were collected, we excluded from transmission analysis all probands in the ascertained sibships. After bias correction, the distribution ratio of the mutated alleles was calculated from the observed genotypes of the offspring of nuclear families and was compared to the expected ratio of 50% according to Mendelian inheritance (one-sample Z-test). Sex ratio, phenotype of the transmitting parent, and transmission depending on the severity of the mutation were also analyzed. Transmission analysis was performed in 114 nuclear families and included 250 descendants. The fertility rates were similar between male and female patients. We showed an excess of transmission from mother to offspring of mutated alleles (59%, p = .022), which was greater when the mutations were severe (61.7%, p = .023). Similarly, an excess of transmission was found when the mother had a PHP1A phenotype (64.7%, p = .036). By contrast, a Mendelian distribution was observed when the mutations were paternally inherited. Higher numbers of females within the carriers, but not in noncarriers, were also observed. The mother-specific transmission ratio distortion (TRD) and the sex-ratio imbalance associated to PHP1A point to a role of Gs α in oocyte biology or embryogenesis, with implications for genetic counseling. © 2019 American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Sarah Snanoudj
- Normandie Université, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, Caen, France
| | - Arnaud Molin
- Normandie Université, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, Caen, France
| | - Cindy Colson
- Normandie Université, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, Caen, France
| | - Nadia Coudray
- Normandie Université, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, Caen, France
| | - Sylvie Paulien
- Normandie Université, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, Caen, France
| | - Hervé Mittre
- Normandie Université, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, Caen, France
| | - Marion Gérard
- Normandie Université, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, Caen, France
| | - Elise Schaefer
- Department of Genetics, CHU de Strasbourg, Strasbourg, France
| | | | - Justine Bacchetta
- Department of Pediatric Nephrology, Rheumatology and Dermatology, CHU de Lyon, Bron, France
| | - Sylvie Odent
- Department of Genetics, CHU de Rennes, Rennes, France
| | - Sophie Naudion
- Department of Genetics, CHU de Bordeaux, Bordeaux, France
| | | | | | - Nicolas Gruchy
- Normandie Université, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, Caen, France
| | - Marie-Laure Kottler
- Normandie Université, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, Caen, France
| | - Nicolas Richard
- Normandie Université, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, Caen, France
| |
Collapse
|
19
|
Grelet M, Blanck V, Sigaudy S, Philip N, Giuliano F, Khachnaoui K, Morel G, Grotto S, Sophie J, Poirsier C, Lespinasse J, Alric L, Calvas P, Chalhoub G, Layet V, Molin A, Colson C, Marsili L, Edery P, Lévy N, De Sandre-Giovannoli A. Outcomes of 4 years of molecular genetic diagnosis on a panel of genes involved in premature aging syndromes, including laminopathies and related disorders. Orphanet J Rare Dis 2019; 14:288. [PMID: 31829210 PMCID: PMC6907233 DOI: 10.1186/s13023-019-1189-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2019] [Accepted: 08/30/2019] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Segmental progeroid syndromes are a heterogeneous group of rare and often severe genetic disorders that have been studied since the twentieth century. These progeroid syndromes are defined as segmental because only some of the features observed during natural aging are accelerated. METHODS Since 2015, the Molecular Genetics Laboratory in Marseille La Timone Hospital proposes molecular diagnosis of premature aging syndromes including laminopathies and related disorders upon NGS sequencing of a panel of 82 genes involved in these syndromes. We analyzed the results obtained in 4 years on 66 patients issued from France and abroad. RESULTS Globally, pathogenic or likely pathogenic variants (ACMG class 5 or 4) were identified in about 1/4 of the cases; among these, 9 pathogenic variants were novel. On the other hand, the diagnostic yield of our panel was over 60% when the patients were addressed upon a nosologically specific clinical suspicion, excepted for connective tissue disorders, for which clinical diagnosis may be more challenging. Prenatal testing was proposed to 3 families. We additionally detected 16 variants of uncertain significance and reclassified 3 of them as benign upon segregation analysis in first degree relatives. CONCLUSIONS High throughput sequencing using the Laminopathies/ Premature Aging disorders panel allowed molecular diagnosis of rare disorders associated with premature aging features and genetic counseling for families, representing an interesting first-level analysis before whole genome sequencing may be proposed, as a future second step, by the National high throughput sequencing platforms ("Medicine France Genomics 2025" Plan), in families without molecular diagnosis.
Collapse
Affiliation(s)
- Maude Grelet
- Department of Medical Genetics, Assistance Publique Hopitaux de Marseille, Marseille, France.,Aix Marseille Univ, INSERM, MMG, Marseille, France
| | - Véronique Blanck
- Department of Medical Genetics, Assistance Publique Hopitaux de Marseille, Marseille, France
| | - Sabine Sigaudy
- Department of Medical Genetics, Assistance Publique Hopitaux de Marseille, Marseille, France.,Aix Marseille Univ, INSERM, MMG, Marseille, France
| | - Nicole Philip
- Department of Medical Genetics, Assistance Publique Hopitaux de Marseille, Marseille, France.,Aix Marseille Univ, INSERM, MMG, Marseille, France
| | | | | | - Godelieve Morel
- Hospices Civils de Lyon, Genetic Department and National HHT Reference Center, Femme-Mère-Enfants Hospital, F-69677, Bron, France.,Université Claude Bernard Lyon 1, F-69100, Villeurbanne, France
| | - Sarah Grotto
- Genetics Department, AP-HP, Robert-Debré University Hospital, Paris, France
| | - Julia Sophie
- Department of Medical Genetics, CHU Toulouse, Purpan Hospital, 31059, Toulouse, France
| | - Céline Poirsier
- Department of Genetics, Reims University Hospital, Reims, France
| | - James Lespinasse
- Department of Genetics, Centre Hospitalier de Chambéry- Hôtel-dieu, Chambery, France
| | - Laurent Alric
- Internal Medicine, CHU Toulouse, Rangueil Hospital, Toulouse 3 University Hospital Center, Toulouse, France
| | - Patrick Calvas
- Department of Medical Genetics, CHU Toulouse, Purpan Hospital, 31059, Toulouse, France
| | | | - Valérie Layet
- Department of Genetics, Le Havre Hospital, F76600, Le Havre, France
| | - Arnaud Molin
- Department of Genetics, CHU de Caen, Avenue de la Cote de Nacre, 14000, Caen, France
| | - Cindy Colson
- Department of Genetics, CHU de Caen, Avenue de la Cote de Nacre, 14000, Caen, France
| | - Luisa Marsili
- Department of Clinical Genetics, Lille University Hospital, CHU, Lille, France
| | - Patrick Edery
- Hospices Civils de Lyon, Genetic Department and National HHT Reference Center, Femme-Mère-Enfants Hospital, F-69677, Bron, France.,Université Claude Bernard Lyon 1, F-69100, Villeurbanne, France
| | - Nicolas Lévy
- Department of Medical Genetics, Assistance Publique Hopitaux de Marseille, Marseille, France.,Aix Marseille Univ, INSERM, MMG, Marseille, France.,CRB-TAC (Biological Ressource Center-Tissues, DNA, Cells), Assistance Publique Hopitaux de Marseille, Marseille, France
| | - Annachiara De Sandre-Giovannoli
- Department of Medical Genetics, Assistance Publique Hopitaux de Marseille, Marseille, France. .,Aix Marseille Univ, INSERM, MMG, Marseille, France. .,CRB-TAC (Biological Ressource Center-Tissues, DNA, Cells), Assistance Publique Hopitaux de Marseille, Marseille, France.
| |
Collapse
|
20
|
Colson C, Decamp M, Gruchy N, Coudray N, Ballandonne C, Bracquemart C, Molin A, Mittre H, Takatani R, Jüppner H, Kottler ML, Richard N. High frequency of paternal iso or heterodisomy at chromosome 20 associated with sporadic pseudohypoparathyroidism 1B. Bone 2019; 123:145-152. [PMID: 30905746 PMCID: PMC6637416 DOI: 10.1016/j.bone.2019.03.023] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 03/04/2019] [Accepted: 03/18/2019] [Indexed: 12/20/2022]
Abstract
Pseudohypoparathyroidism 1B (PHP1B) is caused by maternal epigenetic defects in the imprinted GNAS cluster. PHP1B can follow an autosomal dominant mode of inheritance or occur sporadically (spor-PHP1B). These latter patients present broad methylation changes of two or more differentially methylated regions (DMR) that, when mimicking the paternal allele, raises the suspicious of the occurrence of paternal uniparental disomy of chromosome 20 (upd(20)pat). A cohort of 33 spor-PHP1B patients was screened for upd(20)pat using comparative genomic hybridization with SNP-chip. Methylation analyses were assessed by methylation specific-multiplex ligation-dependent probe amplification. Upd(20)pat was identified in 6 patients, all exhibiting typical paternal methylation pattern compared to normal controls, namely a complete loss of methylation of GNAS A/B:TSS-DMR, negligible methylation at GNAS-AS1:TSS-DMR and GNAS-XL:Ex1-DMR and complete gain of methylation at GNAS-NESP:TSS-DMR. The overall frequency of upd(20) is 18% in our cohort when searched considering both severe and partial loss of imprinting. However, twenty five patients displayed severe methylation pattern and the upd(20)pat frequency reaches 24% when searching in this group. Consequently, up to day, upd(20)pat is the most common anomaly than other genetic alterations in spor-PHP1B patients. Upd(20)pat occurrence is not linked to the parental age in contrast to upd(20)mat, strongly associated with an advanced maternal childbearing age. This study provides criteria to guide further investigations for upd(20)pat needed for an adequate genetic counseling.
Collapse
Affiliation(s)
- Cindy Colson
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center fo Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, 14000 Caen, France
| | - Matthieu Decamp
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center fo Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, 14000 Caen, France
| | - Nicolas Gruchy
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center fo Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, 14000 Caen, France
| | - Nadia Coudray
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center fo Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, 14000 Caen, France
| | - Céline Ballandonne
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center fo Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, 14000 Caen, France
| | - Claire Bracquemart
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center fo Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, 14000 Caen, France
| | - Arnaud Molin
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center fo Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, 14000 Caen, France
| | - Hervé Mittre
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center fo Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, 14000 Caen, France
| | - Rieko Takatani
- Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Harald Jüppner
- Endocrine Unit and Pediatric Nephrology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
| | - Marie-Laure Kottler
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center fo Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, 14000 Caen, France
| | - Nicolas Richard
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Genetics, Reference Center fo Rare Diseases of Calcium and Phosphorus Metabolism, EA7450 BioTARGen, 14000 Caen, France.
| |
Collapse
|
21
|
Bertholet-Thomas A, Tram N, Dubourg L, Lemoine S, Molin A, Bacchetta J. Fluconazole as a New Therapeutic Tool to Manage Patients With NPTIIc (SLC34A3) Mutation: A Case Report. Am J Kidney Dis 2019; 73:886-889. [DOI: 10.1053/j.ajkd.2018.12.026] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Accepted: 12/06/2018] [Indexed: 11/11/2022]
|
22
|
Karolak JA, Vincent M, Deutsch G, Gambin T, Cogné B, Pichon O, Vetrini F, Mefford HC, Dines JN, Golden-Grant K, Dipple K, Freed AS, Leppig KA, Dishop M, Mowat D, Bennetts B, Gifford AJ, Weber MA, Lee AF, Boerkoel CF, Bartell TM, Ward-Melver C, Besnard T, Petit F, Bache I, Tümer Z, Denis-Musquer M, Joubert M, Martinovic J, Bénéteau C, Molin A, Carles D, André G, Bieth E, Chassaing N, Devisme L, Chalabreysse L, Pasquier L, Secq V, Don M, Orsaria M, Missirian C, Mortreux J, Sanlaville D, Pons L, Küry S, Bézieau S, Liet JM, Joram N, Bihouée T, Scott DA, Brown CW, Scaglia F, Tsai ACH, Grange DK, Phillips JA, Pfotenhauer JP, Jhangiani SN, Gonzaga-Jauregui CG, Chung WK, Schauer GM, Lipson MH, Mercer CL, van Haeringen A, Liu Q, Popek E, Coban Akdemir ZH, Lupski JR, Szafranski P, Isidor B, Le Caignec C, Stankiewicz P. Complex Compound Inheritance of Lethal Lung Developmental Disorders Due to Disruption of the TBX-FGF Pathway. Am J Hum Genet 2019; 104:213-228. [PMID: 30639323 DOI: 10.1016/j.ajhg.2018.12.010] [Citation(s) in RCA: 65] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Accepted: 12/13/2018] [Indexed: 12/24/2022] Open
Abstract
Primary defects in lung branching morphogenesis, resulting in neonatal lethal pulmonary hypoplasias, are incompletely understood. To elucidate the pathogenetics of human lung development, we studied a unique collection of samples obtained from deceased individuals with clinically and histopathologically diagnosed interstitial neonatal lung disorders: acinar dysplasia (n = 14), congenital alveolar dysplasia (n = 2), and other lethal lung hypoplasias (n = 10). We identified rare heterozygous copy-number variant deletions or single-nucleotide variants (SNVs) involving TBX4 (n = 8 and n = 2, respectively) or FGF10 (n = 2 and n = 2, respectively) in 16/26 (61%) individuals. In addition to TBX4, the overlapping ∼2 Mb recurrent and nonrecurrent deletions at 17q23.1q23.2 identified in seven individuals with lung hypoplasia also remove a lung-specific enhancer region. Individuals with coding variants involving either TBX4 or FGF10 also harbored at least one non-coding SNV in the predicted lung-specific enhancer region, which was absent in 13 control individuals with the overlapping deletions but without any structural lung anomalies. The occurrence of rare coding variants involving TBX4 or FGF10 with the putative hypomorphic non-coding SNVs implies a complex compound inheritance of these pulmonary hypoplasias. Moreover, they support the importance of TBX4-FGF10-FGFR2 epithelial-mesenchymal signaling in human lung organogenesis and help to explain the histopathological continuum observed in these rare lethal developmental disorders of the lung.
Collapse
MESH Headings
- DNA Copy Number Variations/genetics
- Female
- Fibroblast Growth Factor 10/genetics
- Fibroblast Growth Factor 10/metabolism
- Gene Expression Regulation
- Gestational Age
- Humans
- Infant, Newborn
- Infant, Newborn, Diseases/genetics
- Infant, Newborn, Diseases/metabolism
- Infant, Newborn, Diseases/mortality
- Infant, Newborn, Diseases/pathology
- Lung/embryology
- Lung/growth & development
- Lung Diseases/genetics
- Lung Diseases/metabolism
- Lung Diseases/mortality
- Lung Diseases/pathology
- Male
- Maternal Inheritance
- Organogenesis
- Paternal Inheritance
- Pedigree
- Polymorphism, Single Nucleotide/genetics
- Receptor, Fibroblast Growth Factor, Type 2/metabolism
- Signal Transduction/genetics
- T-Box Domain Proteins/genetics
- T-Box Domain Proteins/metabolism
Collapse
Affiliation(s)
- Justyna A Karolak
- Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Department of Genetics and Pharmaceutical Microbiology, Poznan University of Medical Sciences, 60-781 Poznan, Poland
| | - Marie Vincent
- Service de Génétique Médicale, CHU de Nantes, 44000 Nantes, France; Inserm, CNRS, Univ Nantes, l'institut du thorax, 44000 Nantes, France
| | - Gail Deutsch
- Department of Pathology, Seattle Children's Hospital, Seattle, WA 98105, USA
| | - Tomasz Gambin
- Department of Medical Genetics, Institute of Mother and Child, 01-211 Warsaw, Poland; Institute of Computer Science, Warsaw University of Technology, 00-665 Warsaw, Poland
| | - Benjamin Cogné
- Service de Génétique Médicale, CHU de Nantes, 44000 Nantes, France; Inserm, CNRS, Univ Nantes, l'institut du thorax, 44000 Nantes, France
| | - Olivier Pichon
- Service de Génétique Médicale, CHU de Nantes, 44000 Nantes, France
| | | | - Heather C Mefford
- Department of Pediatrics, Division of Genetic Medicine, University of Washington, Seattle, WA 98195, USA
| | - Jennifer N Dines
- Department of Pediatrics, Division of Genetic Medicine, University of Washington, Seattle, WA 98195, USA; Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA
| | - Katie Golden-Grant
- Division of Genetic Medicine, Seattle Children's Hospital, Seattle, WA 98105, USA
| | - Katrina Dipple
- Department of Pediatrics, Division of Genetic Medicine, University of Washington, Seattle, WA 98195, USA; Division of Genetic Medicine, Seattle Children's Hospital, Seattle, WA 98105, USA
| | - Amanda S Freed
- Department of Pediatrics, Division of Genetic Medicine, University of Washington, Seattle, WA 98195, USA; Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA
| | - Kathleen A Leppig
- Genetic Services Kaiser Permanente of Washington, Seattle, WA 98112, USA
| | - Megan Dishop
- Pathology and Laboratory Medicine, Phoenix Children's Hospital, Phoenix, AZ 85016, USA
| | - David Mowat
- Centre for Clinical Genetics, Sydney Children's Hospital, Randwick Sydney, NSW 2031 Australia; School of Women's and Children's Health, The University of New South Wales, Sydney, NSW 2052, Australia
| | - Bruce Bennetts
- Discipline of Child & Adolescent Health, Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia; Molecular Genetics Department, Western Sydney Genetics Program, The Children's Hospital at Westmead, Sydney, NSW 2145, Australia; Discipline of Genetic Medicine, Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia
| | - Andrew J Gifford
- School of Women's and Children's Health, The University of New South Wales, Sydney, NSW 2052, Australia; Department of Anatomical Pathology, Prince of Wales Hospital, Randwick, NSW 2031, Australia
| | - Martin A Weber
- Department of Anatomical Pathology, Prince of Wales Hospital, Randwick, NSW 2031, Australia; School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia
| | - Anna F Lee
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada
| | - Cornelius F Boerkoel
- Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada
| | - Tina M Bartell
- Department of Genetics, Kaiser Permanente Sacramento Medical Center, Sacramento, CA 95815, USA
| | | | - Thomas Besnard
- Service de Génétique Médicale, CHU de Nantes, 44000 Nantes, France; Inserm, CNRS, Univ Nantes, l'institut du thorax, 44000 Nantes, France
| | - Florence Petit
- Service de Génétique Clinique, CHU Lille, 59000 Lille, France
| | - Iben Bache
- Department of Cellular and Molecular Medicine, University of Copenhagen, 2200 N Copenhagen, Denmark; Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, 2100 Ø Copenhagen, Denmark
| | - Zeynep Tümer
- Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, 2600 Glostrup, Copenhagen, Denmark; Deparment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 N, Copenhagen, Denmark
| | | | | | - Jelena Martinovic
- Unit of Fetal Pathology, AP-HP, Antoine Beclere Hospital, 75000 Paris, France
| | - Claire Bénéteau
- Service de Génétique Médicale, CHU de Nantes, 44000 Nantes, France; Inserm, CNRS, Univ Nantes, l'institut du thorax, 44000 Nantes, France
| | - Arnaud Molin
- Service de Génétique Médicale, CHU Caen, 14000 Caen, France
| | - Dominique Carles
- Service d'anatomo-pathologie, CHU Bordeaux, 33000 Bordeaux, France
| | - Gwenaelle André
- Service d'anatomo-pathologie, CHU Bordeaux, 33000 Bordeaux, France
| | - Eric Bieth
- Service de génétique médicale, CHU Toulouse, France and UDEAR, UMR 1056 Inserm - Université de Toulouse, 31000 Toulouse, France
| | - Nicolas Chassaing
- Service de génétique médicale, CHU Toulouse, France and UDEAR, UMR 1056 Inserm - Université de Toulouse, 31000 Toulouse, France
| | | | | | | | - Véronique Secq
- Aix Marseille Univ, APHM, Hôpital Nord, Service d'anatomo-pathologie, 13000 Marseille, France
| | - Massimiliano Don
- Sant'Antonio General Hospital, Pediatric Care Unit, San Daniele del Friuli, 33100 Udine, Italy
| | - Maria Orsaria
- Department of Medical and Biological Sciences, Pathology Unit, University of Udine, Udine, Italy
| | - Chantal Missirian
- Aix Marseille Univ, APHM, INSERM, MMG, Marseille, Timone Hospital, 13000 Marseille, France
| | - Jérémie Mortreux
- Aix Marseille Univ, APHM, INSERM, MMG, Marseille, Timone Hospital, 13000 Marseille, France
| | - Damien Sanlaville
- Hospices Civils de Lyon, GHE, Genetics department, and Lyon University, 69000 Lyon, France
| | - Linda Pons
- Hospices Civils de Lyon, GHE, Genetics department, and Lyon University, 69000 Lyon, France
| | - Sébastien Küry
- Service de Génétique Médicale, CHU de Nantes, 44000 Nantes, France; Inserm, CNRS, Univ Nantes, l'institut du thorax, 44000 Nantes, France
| | - Stéphane Bézieau
- Service de Génétique Médicale, CHU de Nantes, 44000 Nantes, France; Inserm, CNRS, Univ Nantes, l'institut du thorax, 44000 Nantes, France
| | - Jean-Michel Liet
- Service de réanimation pédiatrique, CHU Nantes, 44000 Nantes, France
| | - Nicolas Joram
- Service de réanimation pédiatrique, CHU Nantes, 44000 Nantes, France
| | | | - Daryl A Scott
- Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Chester W Brown
- Department of Pediatrics, Genetics Division, University of Tennessee Health Science Center, Memphis, TN 38163, USA
| | - Fernando Scaglia
- Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children's Hospital, Houston, TX 77030, USA; Joint BCM-CUHK Center of Medical Genetics, Prince of Wales Hospital, ShaTin, New Territories, Hong Kong SAR
| | - Anne Chun-Hui Tsai
- Department of Pediatrics, The Children's Hospital, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Dorothy K Grange
- Department of Pediatrics, Division of Genetics and Genomic Medicine, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO 63110, USA
| | - John A Phillips
- Department of Pediatrics, Division of Medical Genetics and Genomic Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Jean P Pfotenhauer
- Department of Pediatrics, Division of Medical Genetics and Genomic Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Shalini N Jhangiani
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA
| | | | - Wendy K Chung
- Departments of Pediatrics and Medicine, Columbia University, New York, NY 10032, USA
| | - Galen M Schauer
- Department of Pathology, Kaiser Permanente Oakland Medical Center, Oakland, CA 94611, USA
| | - Mark H Lipson
- Department of Genetics, Kaiser Permanente Sacramento Medical Center, Sacramento, CA 95815, USA
| | - Catherine L Mercer
- Wessex Clinical Genetics Service, University Hospital Southampton NHS Foundation Trust, Princess Anne Hospital, Southampton SO16 5YA, UK
| | - Arie van Haeringen
- Department of Clinical Genetics, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands
| | - Qian Liu
- Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Edwina Popek
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA
| | - Zeynep H Coban Akdemir
- Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | - James R Lupski
- Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children's Hospital, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Przemyslaw Szafranski
- Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Bertrand Isidor
- Service de Génétique Médicale, CHU de Nantes, 44000 Nantes, France; Inserm, CNRS, Univ Nantes, l'institut du thorax, 44000 Nantes, France
| | | | - Paweł Stankiewicz
- Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Baylor Genetics, Houston, TX 77021, USA; Institute of Mother and Child, 01-211 Warsaw, Poland.
| |
Collapse
|
23
|
Lambert JC, Baudart P, De Sandre-Giovannoli A, Molin A, Marcelli C. Lamin A/C gene (LMNA) mutation associated with laminopathy: A rare cause of idiopathic acro-osteolysis. Joint Bone Spine 2018; 86:525-527. [PMID: 30528549 DOI: 10.1016/j.jbspin.2018.11.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Accepted: 11/28/2018] [Indexed: 12/22/2022]
Affiliation(s)
| | - Pauline Baudart
- CHU de Caen, department of rheumatology, avenue de la Côte de Nacre, Caen, 14000, France
| | - Annachiara De Sandre-Giovannoli
- AP-HM, department of medical genetics, La Timone Children's hospital, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France
| | - Arnaud Molin
- CHU de Caen, department of genetics, avenue de la Cote de Nacre, Caen, 14000, France
| | - Christian Marcelli
- CHU de Caen, department of rheumatology, avenue de la Côte de Nacre, Caen, 14000, France; Université Caen Normandie, medical School, Caen, 14000, France
| |
Collapse
|
24
|
Abid N, Lemoine S, Molin A, Normand G, Bertholet-Thomas A, Bacchetta J, Juillard L, Badet L, Dubourg L. Une nouvelle étiologie dans la lithiase calcique récidivante : la mutation hétérozygote du gène de la 24 hydroxylase. Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
25
|
Hureaux M, Molin A, Jay N, Saliou AH, Spaggiari E, Salomon R, Benachi A, Vargas-Poussou R, Heidet L. Prenatal hyperechogenic kidneys in three cases of infantile hypercalcemia associated with SLC34A1 mutations. Pediatr Nephrol 2018; 33:1723-1729. [PMID: 29959532 DOI: 10.1007/s00467-018-3998-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Revised: 05/21/2018] [Accepted: 05/25/2018] [Indexed: 01/13/2023]
Abstract
BACKGROUND Prenatal diagnosis of hyperechogenic kidneys is associated with a wide range of etiologies and prognoses. The recent advances in fetal ultrasound associated with the development of next-generation sequencing for molecular analysis have enlarged the spectrum of etiologies, making antenatal diagnosis a very challenging discipline. Of the various known causes of hyperechogenic fetal kidneys, calcium and phosphate metabolism disorders represent a rare cause. An accurate diagnosis is crucial for providing appropriate genetic counseling and medical follow-up after birth. METHODS We report on three cases of fetal hyperechogenic kidneys corresponding to postnatal diagnosis of nephrocalcinosis. In all cases, antenatal ultrasound showed hyperechogenic kidneys of normal to large size from 22 gestational weeks, with a normal amount of amniotic fluid. Postnatal ultrasound follow-up showed nephrocalcinosis associated with hypercalcemia, hypercalciuria, elevated 1,25(OH)2-vitamin D, and suppressed parathyroid hormone levels. RESULTS Molecular genetic analysis by next-generation sequencing performed after birth in the three newborns revealed biallelic pathogenic variants in the SLC34A1 gene, encoding the sodium/phosphate cotransporter type 2 (Npt2a), confirming the diagnosis of infantile hypercalcemia. CONCLUSIONS Nephrocalcinosis due to infantile hypercalcemia can be a cause of fetal hyperechogenic kidneys, which suggests early antenatal anomaly of calcium and phosphate metabolism. This entity should be considered in differential diagnosis. Postnatal follow-up of infants with hyperechogenic kidneys should include evaluation of calcium and phosphate metabolism.
Collapse
Affiliation(s)
- Marguerite Hureaux
- Département de Génétique, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, 20-40 rue Leblanc, 75015, Paris, France.,Paris Descartes-Sorbonne Paris Cité University, Paris, France.,Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Filière ORKiD, Paris, France
| | - Arnaud Molin
- Service de Génétique, Centre Hospitalier Universitaire de Caen, Caen, France.,Centre de Référence des Maladies rares du Métabolisme du calcium et du phosphate (filière OSCAR), FilièreOSCAR, Paris, France.,Université Caen Normandie, UFR de médecine (Medical School), EA7450 BioTarGen, Caen, France
| | - Nadine Jay
- Centre Hospitalier Universitaire de Brest, Service de Pédiatrie et Génétique Médicale, Brest, France
| | | | - Emmanuel Spaggiari
- Département de Gynécologie-Obstétrique, Assistance Publique Hôpitaux de Paris, Hôpital Necker - Enfants Malades, Paris, France
| | - Rémi Salomon
- Paris Descartes-Sorbonne Paris Cité University, Paris, France.,Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Filière ORKiD, Paris, France.,Département de Néphrologie Pédiatrique, Assistance Publique Hôpitaux de Paris, Hôpital Necker - Enfants Malades, Paris, France
| | - Alexandra Benachi
- Département de Gynécologie-Obstétrique, Assistance Publique Hôpitaux de Paris, Hôpital Antoine-Béclère, Université Paris-Sud, Clamart, France
| | - Rosa Vargas-Poussou
- Département de Génétique, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, 20-40 rue Leblanc, 75015, Paris, France. .,Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Filière ORKiD, Paris, France.
| | - Laurence Heidet
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Filière ORKiD, Paris, France.,Département de Néphrologie Pédiatrique, Assistance Publique Hôpitaux de Paris, Hôpital Necker - Enfants Malades, Paris, France
| |
Collapse
|
26
|
Lemoine S, Molin A, Abid N, Normand G, Betholet-Thomas A, Bacchetta J, Juillard L, Dubourg L. Une nouvelle étiologie dans la lithiase calcique récidivante : la mutation hétérozygote du gène de la 24 hydroxylase. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
27
|
Berar M, Balouet P, Chappey C, Dreyfus M, Molin A, Benoist G. [Antenatal diagnosis of an umbilical cord hemangioma]. ACTA ACUST UNITED AC 2018; 46:610-613. [PMID: 29958835 DOI: 10.1016/j.gofs.2018.05.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2018] [Indexed: 11/19/2022]
Affiliation(s)
- M Berar
- Service de gynécologie obstétrique et médecine de la reproduction, CHU Côte-de-Nacre, 14000 Caen, France; Université de Caen-Normandie, 14000 Caen, France
| | - P Balouet
- Service de gynécologie obstétrique, centre hospitalier Mémorial-Saint-Lô, 50000 Saint-Lô, France
| | - C Chappey
- Service de gynécologie obstétrique et médecine de la reproduction, CHU Côte-de-Nacre, 14000 Caen, France; Université de Caen-Normandie, 14000 Caen, France
| | - M Dreyfus
- Service de gynécologie obstétrique et médecine de la reproduction, CHU Côte-de-Nacre, 14000 Caen, France; Université de Caen-Normandie, 14000 Caen, France
| | - A Molin
- Service d'anatomo-pathologie, CHU Côte-de-Nacre, 14000 Caen, France
| | - G Benoist
- Service de gynécologie obstétrique et médecine de la reproduction, CHU Côte-de-Nacre, 14000 Caen, France; Université de Caen-Normandie, 14000 Caen, France.
| |
Collapse
|
28
|
Molin A, Vasilyeva N. Duration of remission and features of the subjective picture of the world in adults with dependence on psychoactive substances. psy 2018. [DOI: 10.31857/s020595920000073-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
29
|
Battaglini D, Brunetti I, Molin A, Tarantino F, Sorbello M, Mora F, Peretti G, Pelosi P. Postintubation tracheal stenosis: A case report. Trends in Anaesthesia and Critical Care 2017. [DOI: 10.1016/j.tacc.2017.10.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
30
|
Molin A, Wiedemann A, Demers N, Kaufmann M, Do Cao J, Mainard L, Dousset B, Journeau P, Abeguile G, Coudray N, Mittre H, Richard N, Weryha G, Sorlin A, Jones G, Kottler ML, Feillet F. Vitamin D-Dependent Rickets Type 1B (25-Hydroxylase Deficiency): A Rare Condition or a Misdiagnosed Condition? J Bone Miner Res 2017; 32:1893-1899. [PMID: 28548312 DOI: 10.1002/jbmr.3181] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 05/22/2017] [Accepted: 05/25/2017] [Indexed: 11/05/2022]
Abstract
Vitamin D requires a two-step activation by hydroxylation: The first step is catalyzed by hepatic 25-hydroxylase (CYP2R1, 11p15.2) and the second one is catalyzed by renal 1α-hydroxylase (CYP27B1, 12q13.1), which produces the active hormonal form of 1,25-(OH)2 D. Mutations of CYP2R1 have been associated with vitamin D-dependent rickets type 1B (VDDR1B), a very rare condition that has only been reported to affect 4 families to date. We describe 7 patients from 2 unrelated families who presented with homozygous loss-of-function mutations of CYP2R1. Heterozygous mutations were present in their normal parents. We identified a new c.124_138delinsCGG (p.Gly42_Leu46delinsArg) variation and the previously published c.296T>C (p.Leu99Pro) mutation. Functional in vitro studies confirmed loss-of-function enzymatic activity in both cases. We discuss the difficulties in establishing the correct diagnosis and the specific biochemical pattern, namely, very low 25-OH-D suggestive of classical vitamin D deficiency, in the face of normal/high concentrations of 1,25-(OH)2 D. Siblings exhibited the three stages of rickets based on biochemical and radiographic findings. Interestingly, adult patients were able to maintain normal mineral metabolism without vitamin D supplementation. One index case presented with a partial improvement with 1alfa-hydroxyvitamin D3 or alfacalcidol (1α-OH-D3 ) treatment, and we observed a dramatic increase in the 1,25-(OH)2 D serum concentration, which indicated the role of accessory 25-hydroxylase enzymes. Lastly, in patients who received calcifediol (25-OH-D3 ), we documented normal 24-hydroxylase activity (CYP24A1). For the first time, and according to the concept of personalized medicine, we demonstrate dramatic improvements in patients who were given 25-OH-D therapy (clinical symptoms, biochemical data, and bone densitometry). In conclusion, the current study further expands the CYP2R1 mutation spectrum. We note that VDDR1B could be easily mistaken for classical vitamin D deficiency. © 2017 American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Arnaud Molin
- CHU de Caen, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, Caen, France.,Université Caen Normandie, Medical School, Caen, France.,BioTARGEN, Université Caen Normandie, Caen, France.,OeReCa, Université Caen Normandie, Caen, France
| | - Arnaud Wiedemann
- CHU de Nancy, Department of Pediatrics and Reference Center for Rare Hereditary Diseases of Metabolism, Vandoeuvre-lès-Nancy, France.,Université de Lorraine, Medical School, Vandoeuvre-lès-Nancy, France
| | - Nick Demers
- Queen's University, Department of Biomedical and Molecular Sciences, Kingston, Canada
| | - Martin Kaufmann
- Queen's University, Department of Biomedical and Molecular Sciences, Kingston, Canada
| | - Jérémy Do Cao
- CHU de Nancy, Department of Pediatrics and Reference Center for Rare Hereditary Diseases of Metabolism, Vandoeuvre-lès-Nancy, France.,Université de Lorraine, Medical School, Vandoeuvre-lès-Nancy, France
| | - Laurent Mainard
- Université de Lorraine, Medical School, Vandoeuvre-lès-Nancy, France.,CHU de Nancy, Department of Radiology, Vandoeuvre-lès-Nancy, France
| | - Brigitte Dousset
- CHU de Nancy, Department of Biochemistry, Vandoeuvre-lès-Nancy, France
| | - Pierre Journeau
- Université de Lorraine, Medical School, Vandoeuvre-lès-Nancy, France.,CHU de Nancy, Department of Orthopedic Pediatric Surgery, Vandoeuvre-lès-Nancy, France
| | - Geneviève Abeguile
- CHU de Caen, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, Caen, France
| | - Nadia Coudray
- CHU de Caen, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, Caen, France
| | - Hervé Mittre
- CHU de Caen, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, Caen, France.,Université Caen Normandie, Medical School, Caen, France.,OeReCa, Université Caen Normandie, Caen, France
| | - Nicolas Richard
- CHU de Caen, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, Caen, France.,BioTARGEN, Université Caen Normandie, Caen, France
| | - Georges Weryha
- Université de Lorraine, Medical School, Vandoeuvre-lès-Nancy, France.,CHU de Nancy, Department of Endocrinology, Vandoeuvre-lès-Nancy, France
| | - Arthur Sorlin
- CHU de Nancy, Department of Genetics, Vandoeuvre-lès-Nancy, France
| | - Glenville Jones
- Queen's University, Department of Biomedical and Molecular Sciences, Kingston, Canada
| | - Marie-Laure Kottler
- CHU de Caen, Department of Genetics, Molecular Genetics Laboratory and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, Caen, France.,Université Caen Normandie, Medical School, Caen, France.,BioTARGEN, Université Caen Normandie, Caen, France
| | - Francois Feillet
- CHU de Nancy, Department of Pediatrics and Reference Center for Rare Hereditary Diseases of Metabolism, Vandoeuvre-lès-Nancy, France.,Université de Lorraine, Medical School, Vandoeuvre-lès-Nancy, France.,INSERM, U954 Nutrition - génétique et exposition aux risques environnementaux, Vandoeuvre-lès-Nancy, France
| |
Collapse
|
31
|
Kaufmann M, Morse N, Molloy BJ, Cooper DP, Schlingmann KP, Molin A, Kottler ML, Gallagher JC, Armas L, Jones G. Improved Screening Test for Idiopathic Infantile Hypercalcemia Confirms Residual Levels of Serum 24,25-(OH) 2 D 3 in Affected Patients. J Bone Miner Res 2017; 32:1589-1596. [PMID: 28304097 DOI: 10.1002/jbmr.3135] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Revised: 02/22/2017] [Accepted: 03/15/2017] [Indexed: 11/10/2022]
Abstract
CYP24A1 mutations are now accepted as a cause of idiopathic infantile hypercalcemia (IIH). A rapid liquid-chromatography tandem mass spectrometry (LC-MS/MS)-based blood test enabling measurement of the 25-OH-D3 :24,25-(OH)2 D3 ratio (R) can identify IIH patients on the basis of reduced C24-hydroxylation of 25-OH-D3 by CYP24A1 in vivo. Although values of this ratio are significantly elevated in IIH, somewhat surprisingly, serum 24,25-(OH)2 D3 remains detectable. The current study explores possible explanations for this including: residual CYP24A1 enzyme activity in individuals with certain CYP24A1 genotypes, expression of alternative C24-hydroxylases, and the possibility of isobaric contamination of the 24,25-(OH)2 D3 peak on LC-MS/MS. We employed an extended 20-min run time on LC-MS/MS to study serum vitamin D metabolites in patients with IIH due to mutations of CYP24A1 or SLC34A1; in unaffected heterozygotes and dialysis patients; in patients with vitamin D deficiency; as well as in normal subjects exhibiting a broad range of 25-OH-D levels. We identified 25,26-(OH)2 D3 as a contaminant of the 24,25-(OH)2 D3 peak. In normals, the concentration of 24,25-(OH)2 D3 greatly exceeds 25,26-(OH)2 D3 ; however, 25,26-(OH)2 D3 becomes more significant in IIH with CYP24A1 mutations and in dialysis patients, where 24,25-(OH)2 D3 levels are low when CYP24A1 function is compromised. Mean R in 30 IIH-CYP24A1 patients was 700 (range, 166 to 2168; cutoff = 140) as compared with 31 in 163 controls. Furthermore, patients possessing CYP24A1 L409S alleles exhibited higher 24,25-(OH)2 D3 levels and lower R (mean R = 268; n = 8) than patients with other mutations. We conclude that a chromatographic approach which resolves 24,25-(OH)2 D3 from 25,26-(OH)2 D3 produces a more accurate R that can be used to differentiate pathological states where CYP24A1 activity is altered. The origin of the residual serum 24,25-(OH)2 D3 in IIH patients appears to be multifactorial. © 2017 American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Martin Kaufmann
- Department of Biomedical & Molecular Sciences, Queen's University, Kingston, ON, Canada
| | - Nicole Morse
- Department of Biomedical & Molecular Sciences, Queen's University, Kingston, ON, Canada
| | | | | | | | - Arnaud Molin
- Department of Genetics, University de Basse-Normandie, Caen, France.,National Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (Le Centre National de Référence des maladies rares du métabolisme du calcium et du phosphore), Caen University Hospital, Caen, France
| | - Marie Laure Kottler
- Department of Genetics, University de Basse-Normandie, Caen, France.,National Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism (Le Centre National de Référence des maladies rares du métabolisme du calcium et du phosphore), Caen University Hospital, Caen, France
| | - J Christopher Gallagher
- Bone Metabolism Unit, Department of Medicine, Creighton University School of Medicine, Omaha, NE, USA
| | - Laura Armas
- Department of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, USA
| | - Glenville Jones
- Department of Biomedical & Molecular Sciences, Queen's University, Kingston, ON, Canada
| |
Collapse
|
32
|
Laquerriere A, Maillard C, Cavallin M, Chapon F, Marguet F, Molin A, Sigaudy S, Blouet M, Benoist G, Fernandez C, Poirier K, Chelly J, Thomas S, Bahi-Buisson N. Neuropathological Hallmarks of Brain Malformations in Extreme Phenotypes Related to DYNC1H1 Mutations. J Neuropathol Exp Neurol 2017; 76:195-205. [PMID: 28395088 DOI: 10.1093/jnen/nlw124] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Dyneins play a critical role in a wide variety of cellular functions such as the movement of organelles and numerous aspects of mitosis, making it central player in neocortical neurogenesis and migration. Recently, cytoplasmic dynein-1, heavy chain-1 (DYNC1H1) mutations have been found to cause a wide spectrum of brain cortical malformations. We report on the detailed neuropathological features of brain lesions from 2 fetuses aged 36 and 22 weeks of gestation (WG), respectively, carrying de novo DYNC1H1 mutations, p.Arg2720Lys and p.Val3951Ala and presenting the most severe phenotype reported to date. Analysis using the Dictyostelium discoideum dynein motor crystal structure showed that the mutations are both predicted to have deleterious consequences on the function of the motor domain. Both fetuses showed a similar macroscopic and histological brain malformative complex associating bilateral fronto-parietal polymicrogyria (PMG), dysgenesis of the corpus callosum and of the cortico-spinal tracts, along with brainstem and cerebellar abnormalities. Both exhibited extremely severe disrupted cortical lamination. Immunohistochemical studies provided the evidence for defects in cell proliferation and postmitotic neuroblast ability to exit from the subventricular zone resulting in a failure of radial migration toward the cortical plate, thus providing new insights for the understanding of the pathophysiology in these cortical malformations.
Collapse
Affiliation(s)
- Annie Laquerriere
- Department of Pathology, Normandy Centre for Genomic and Personalized Medicine, Normandie University, Rouen University Hospital, NeoVasc Team, UNIROUEN, Inserm U1245, Rouen, France
| | - Camille Maillard
- Paris Descartes - Sorbonne Paris Cité University, Imagine Institute, Paris and INSERM UMR-1163, Embryology and Genetics of Congenital Malformations, Paris France
| | - Mara Cavallin
- Paris Descartes - Sorbonne Paris Cité University, Imagine Institute, Paris and INSERM UMR-1163, Embryology and Genetics of Congenital Malformations, Paris France.,Pediatric Neurology, Necker Enfants Malades University Paris Hospital, APHP, Paris, France
| | | | - Florent Marguet
- Department of Pathology, Normandy Centre for Genomic and Personalized Medicine, Normandie University, Rouen University Hospital, NeoVasc Team, UNIROUEN, Inserm U1245, Rouen, France
| | - Arnaud Molin
- Service de Génétique Pôle Biologie et Pharmacie Rouen University Hôpital, France
| | - Sabine Sigaudy
- Clinical Genetics, Hôpital de La Timone, APHM, Marseille University Hospital, Marseille France
| | - Marie Blouet
- Department of Radiology, Caen University Hospital, Caen France
| | - Guillaume Benoist
- Department of Obstetrics and Gynaecology, Caen University Hospital, Caen France
| | - Carla Fernandez
- Department of Pathology and Neuropathology, La Timone University Hospital, Marseille, France
| | - Karine Poirier
- Inserm, U1016, Institut Cochin, Paris, France.,CNRS, UMR8104, Paris, France.,Denis Diderot School of Medicine, Sorbonne-Paris Cité University, Paris, France
| | - Jamel Chelly
- IGBMC, INSERM U964, CNRS UMR 7104, Université de Strasbourg, Illkirch, France.,Pôle de Biologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Sophie Thomas
- Paris Descartes - Sorbonne Paris Cité University, Imagine Institute, Paris and INSERM UMR-1163, Embryology and Genetics of Congenital Malformations, Paris France
| | - Nadia Bahi-Buisson
- Paris Descartes - Sorbonne Paris Cité University, Imagine Institute, Paris and INSERM UMR-1163, Embryology and Genetics of Congenital Malformations, Paris France.,Pediatric Neurology, Necker Enfants Malades University Paris Hospital, APHP, Paris, France
| |
Collapse
|
33
|
Baudart P, Molin A, Cesini J, Jones G, Kaufmann M, Kottler ML, Marcelli C. Calcium pyrophosphate deposition disease revealing a hypersensitivity to vitamin D. Joint Bone Spine 2017; 84:349-351. [DOI: 10.1016/j.jbspin.2016.11.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Accepted: 11/08/2016] [Indexed: 11/25/2022]
|
34
|
Jones F, Thibon P, Guyot M, Molin A, Jeanne-Pasquier C, Guillois B, Benoist G, Dreyfus M. Practice of pathological examinations in stillbirths: A 10-year retrospective study. J Gynecol Obstet Hum Reprod 2016; 46:61-67. [PMID: 28403958 DOI: 10.1016/j.jgyn.2016.06.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Revised: 05/28/2016] [Accepted: 06/07/2016] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To describe the practice of fetal and placental pathological examinations in a large series of spontaneous stillbirths over 10 years. MATERIALS AND METHODS Inclusion of cases recorded by the Lower Normandy Regional Fetal-Infant Mortality Observatory (observatoire régional de mortalité fœto-infantile) from January 1, 2005 to December 31, 2014. The possible cause of death was coded in accordance with the ReCoDe classification system. RESULTS Seven hundred and forty-four cases were recorded. The placental examinations were conducted in 93.7% of cases (CI95%[91.7-95.3]), increasing over the study period, and an autopsy was proposed in 87.2% of cases (CI95%[84.8-89.6]). Autopsy was conducted less frequently during the most recent period, with parental refusal increasing over time. In multivariate analysis, no factor was associated with a higher frequency of placental examinations, while autopsy was proposed more often under certain circumstances: less than 4 pregnancies (P<10-2), birth weight from 1000 to 1500 grams (P=0.05), singleton (P<10-2), clinical context not suggesting a cause (P<10-3), type 1 or 2 maternity ward (P<10-2), antepartum death (P<10-3). CONCLUSION Placental analysis was almost systematically realized, as suggested by international guidelines. Fetal autopsy was often performed, however only in some specific circumstances. New practice guidance to realize customized fetal autopsies appear to be necessary.
Collapse
Affiliation(s)
- F Jones
- Perinatal Network, CHU de Caen, 14000 Caen, France; Gynecology-Obstetrics Unit, CHU de Caen, 14000 Caen, France.
| | - P Thibon
- Perinatal Network, CHU de Caen, 14000 Caen, France
| | - M Guyot
- Perinatal Network, CHU de Caen, 14000 Caen, France; Gynecology-Obstetrics Unit, CHU de Caen, 14000 Caen, France; Pathological Anatomy Unit, CHU de Caen, 14000 Caen, France
| | - A Molin
- Cytogenetics Unit, CHU de Caen, 14000 Caen, France; Neonatal Unit, CHU de Caen, 14000 Caen, France; Pathological Anatomy Unit, CHU de Caen, 14000 Caen, France
| | - C Jeanne-Pasquier
- Perinatal Network, CHU de Caen, 14000 Caen, France; Pathological Anatomy Unit, CHU de Caen, 14000 Caen, France
| | - B Guillois
- Perinatal Network, CHU de Caen, 14000 Caen, France; Medical School, University of Caen Lower-Normandy, 14000 Caen, France; Neonatal Unit, CHU de Caen, 14000 Caen, France
| | - G Benoist
- Perinatal Network, CHU de Caen, 14000 Caen, France; Gynecology-Obstetrics Unit, CHU de Caen, 14000 Caen, France; Neonatal Unit, CHU de Caen, 14000 Caen, France
| | - M Dreyfus
- Perinatal Network, CHU de Caen, 14000 Caen, France; Gynecology-Obstetrics Unit, CHU de Caen, 14000 Caen, France; Neonatal Unit, CHU de Caen, 14000 Caen, France
| |
Collapse
|
35
|
Loyer C, Leroy C, Molin A, Odou MF, Huglo D, Lion G, Ernst O, Hoffmann M, Porchet N, Carnaille B, Pattou F, Kottler ML, Vantyghem MC. Hyperparathyroidism complicating CYP 24A1 mutations. Annales d'Endocrinologie 2016; 77:615-619. [DOI: 10.1016/j.ando.2016.03.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Revised: 03/28/2016] [Accepted: 03/29/2016] [Indexed: 12/14/2022]
|
36
|
Jones F, Thibon P, Jeanne-Pasquier C, Mandon M, Molin A, Guillois B, Benoist G, Dreyfus M. Changes in fetal autopsy patterns over a 10-year period. Arch Dis Child Fetal Neonatal Ed 2016; 101:F481-2. [PMID: 27354383 DOI: 10.1136/archdischild-2015-310332] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/09/2016] [Indexed: 11/04/2022]
Affiliation(s)
| | | | - Corinne Jeanne-Pasquier
- CHU de Caen, Réseau de Périnatalité, Caen, France Laboratoire de Foeto-pathologie, Service d'Anatomo-pathologie, CHU de Caen, Caen, France
| | - Maria Mandon
- Laboratoire de Foeto-pathologie, Service d'Anatomo-pathologie, CHU de Caen, Caen, France Service de Gynécologie-Obstétrique, CHU de Caen, Caen, France
| | - Arnaud Molin
- Laboratoire de Foeto-pathologie, Service d'Anatomo-pathologie, CHU de Caen, Caen, France Service de Génétique, CHU de Caen, Caen, France Université de Caen Basse-Normandie, Medical School, Caen, France
| | - Bernard Guillois
- CHU de Caen, Réseau de Périnatalité, Caen, France Université de Caen Basse-Normandie, Medical School, Caen, France Service de Néonatologie, CHU de Caen, Caen, France
| | - Guillaume Benoist
- CHU de Caen, Réseau de Périnatalité, Caen, France Service de Gynécologie-Obstétrique, CHU de Caen, Caen, France Université de Caen Basse-Normandie, Medical School, Caen, France
| | - Michel Dreyfus
- CHU de Caen, Réseau de Périnatalité, Caen, France Service de Gynécologie-Obstétrique, CHU de Caen, Caen, France Université de Caen Basse-Normandie, Medical School, Caen, France
| |
Collapse
|
37
|
Kün-Darbois JD, Molin A, Jeanne-Pasquier C, Paré A, Bénateau H, Veyssière A. Facial features in Harlequin ichthyosis: Clinical findings about 4 cases. ACTA ACUST UNITED AC 2015; 117:51-3. [PMID: 26740202 DOI: 10.1016/j.revsto.2015.11.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Revised: 10/12/2015] [Accepted: 11/25/2015] [Indexed: 10/22/2022]
Abstract
We report 4 cases of Harlequin ichthyosis, which is a rare and severe congenital ichthyosis involving the face. Facial appearance consists in severe ectropion, conjonctival edema, eclabium, flattened ears, broadened nose and large, thick, plate-like skin scales. Recent advances in neonatal care have been made, such as retinoid therapy, and have led to an increased survival rate. Early surgical correction of ectropion may be required because of ocular complications.
Collapse
Affiliation(s)
- J-D Kün-Darbois
- Service de chirurgie maxillo-faciale, hôpital Côte de Nacre, CHU de Caen, 14033 Caen cedex, France.
| | - A Molin
- Service d'anatomopathologie, hôpital Côte de Nacre, CHU de Caen, 14033 Caen cedex, France
| | - C Jeanne-Pasquier
- Service d'anatomopathologie, hôpital Côte de Nacre, CHU de Caen, 14033 Caen cedex, France
| | - A Paré
- Service de chirurgie maxillo-faciale, hôpital Côte de Nacre, CHU de Caen, 14033 Caen cedex, France
| | - H Bénateau
- Service de chirurgie maxillo-faciale, hôpital Côte de Nacre, CHU de Caen, 14033 Caen cedex, France
| | - A Veyssière
- Service de chirurgie maxillo-faciale, hôpital Côte de Nacre, CHU de Caen, 14033 Caen cedex, France
| |
Collapse
|
38
|
Molin A, Baudoin R, Kaufmann M, Souberbielle JC, Ryckewaert A, Vantyghem MC, Eckart P, Bacchetta J, Deschenes G, Kesler-Roussey G, Coudray N, Richard N, Wraich M, Bonafiglia Q, Tiulpakov A, Jones G, Kottler ML. CYP24A1 Mutations in a Cohort of Hypercalcemic Patients: Evidence for a Recessive Trait. J Clin Endocrinol Metab 2015. [PMID: 26214117 DOI: 10.1210/jc.2014-4387] [Citation(s) in RCA: 94] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
CONTEXT Loss-of-function mutations of CYP24A1 (which encodes the 25-OH-D3-24-hydroxylase) have recently been reported to cause hypercalcemia. OBJECTIVES The aims of this study were: 1) to evaluate the frequency of CYP24A1 mutations in patients with medical history of hypercalcemia; 2) to show the clinical utility of a simultaneous assay of serum 25-hydroxyvitamin D3 (25-OH-D3) and 24,25-dihydroxyvitamin D3 (24,25-[OH]2D3) by liquid chromatography tandem mass spectrometry (LC-MS/MS); and 3) to investigate biochemical parameters in heterozygous gene carriers with CYP24A1 mutations. PATIENTS AND METHODS We screened for CYP24A1 mutations in 72 patients with serum calcium levels > 2.6 mmol/L and PTH levels < 20 pg/mL and recruited 24 relatives after genetic counseling for subsequent investigations. Vitamin D metabolite concentrations were assessed in a subset of patients by LC-MS/MS and results expressed as a ratio (R) of 25-OH-D3:24,25-(OH)2D3. RESULTS Twenty-five patients with hypercalcemia (35%) harbored CYP24A1 variations. Twenty (28%) had biallelic variations, mostly found in subjects with nephrocalcinosis or renal stones (19/20). Five patients, all neonates, were heterozygous, without renal disease. We describe 15 new variations leading to loss-of-function according to pathogenicity prediction programs, and we functionally characterized 5 of them in vitro. A dramatic increase of R, usually >80, was found in patients harboring biallelic mutations providing evidence in vivo for the loss of CYP24A1 activity. In contrast, R value remains <25 in patients without CYP24A1 mutations. Subjects carrying one mutant allele, hypercalcemic individuals, as well as gene-carrier relatives, had a detectable 24,25-(OH)2D3 level and R < 25, indicating normal 24-hydroxylase activity. CONCLUSION CYP24A1 biallelic mutations are frequently found in patients presenting with hypercalcemia, low PTH, and renal disease. We confirm the accuracy and effectiveness of a novel blood test estimating the ratio between relevant vitamin D metabolites as a useful screening tool for CYP24A1 mutations. Haploinsufficiency is not associated with CYP24A1 deficiency.
Collapse
Affiliation(s)
- A Molin
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - R Baudoin
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - M Kaufmann
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - J C Souberbielle
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - A Ryckewaert
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - M C Vantyghem
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - P Eckart
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - J Bacchetta
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - G Deschenes
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - G Kesler-Roussey
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - N Coudray
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - N Richard
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - M Wraich
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - Q Bonafiglia
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - A Tiulpakov
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - G Jones
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| | - M-L Kottler
- Department of Genetics and Reference Center for Rare Disorders of Calcium and Phosphorus Metabolism (A.M., N.C., N.R., M.-L.K.), University Hospital, 14033 Caen, France; University Caen Basse-Normandie (A.M., M.-L.K.), Medical School, Caen, France; Department of Endocrinology (R.B.), University Hospital, 33000 Bordeaux, France; Department of Biomedical and Molecular Sciences (M.K., M.W., Q.B., G.J.), Queen's University, Kingston, Canada; Department of Physiology (J.C.S.), Necker University Hospital, 75015 Paris, France; Department of Pediatrics (A.R.), University Hospital, 35200 Rennes, France; Department of Endocrinology (M.C.V.), University Hospital, 59000 Lille, France; Department of Pediatrics (P.E.), University Hospital, Caen, France; Department of Pediatrics (J.B.), University Hospital, 69000 Lyon, France; Department of Pediatrics (G.D.), Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France; Nephrology & Pediatrics (G.K.-R.), University Hospital, 44093 Nantes, France; Endocrinology Research Centre (A.T.), Moscow 117036, Russia; and INSERM U1075 COMETE (M.-L.K.), University of Caen Basse-Normandy, 14032 Caen, France
| |
Collapse
|
39
|
Molin A, Lopez-Cazaux S, Pichon O, Vincent M, Isidor B, Le Caignec C. Patients with isolated oligo/hypodontia caused by RUNX2 duplication. Am J Med Genet A 2015; 167:1386-90. [DOI: 10.1002/ajmg.a.37052] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Accepted: 02/22/2015] [Indexed: 01/12/2023]
Affiliation(s)
- Arnaud Molin
- Service de Génétique, Laboratoire de cytogénétique; CHU de Caen; Caen France
| | - Serena Lopez-Cazaux
- Departement d'odontologie pédiatrique; faculté de chirurgie dentaire; Nantes France
- Service d'odontologie conservatrice et pédiatrique; CHU de Nantes; Nantes France
| | - Olivier Pichon
- CHU Nantes, Service de Génétique Médicale; Nantes France
| | - Marie Vincent
- CHU Nantes, Service de Génétique Médicale; Nantes France
| | - Bertrand Isidor
- CHU Nantes, Service de Génétique Médicale; Nantes France
- INSERM; UMR-957; Laboratoire de physiopathologie de la résorption osseuse et thérapie des tumeurs osseuses primitives; Nantes France
| | - Cédric Le Caignec
- CHU Nantes, Service de Génétique Médicale; Nantes France
- INSERM; UMR-957; Laboratoire de physiopathologie de la résorption osseuse et thérapie des tumeurs osseuses primitives; Nantes France
| |
Collapse
|
40
|
Stewart Z, Molin A, Leporrier N, Belloy F, Jeanne-Pasquier C, Gérard M, Rozenberg F, Lebon P, Creveaux I, Benoist G. Prenatal diagnosis of Aicardi-Goutières syndrome: a sonographic mimicry of cytomegalovirus fetopathy. J Ultrasound Med 2015; 34:169-171. [PMID: 25542954 DOI: 10.7863/ultra.34.1.169] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Affiliation(s)
- Zelda Stewart
- Department of Gynecology, Obstetrics, and Reproductive Medicine (Z.S., G.B.), Department of Medical Genetics (A.M., N.L., M.G.), Department of Pediatric Radiology (F.B.), Department of Fetopathology (C.J.-P.), University of Caen, Caen, France, Department of Virology, Saint Vincent de Paul Hospital, Paris, France (F.R., P.L.), Department of Genetics, University of Clermont-Ferrand, Clermont-Ferrand, France (I.C.)
| | - Arnaud Molin
- Department of Gynecology, Obstetrics, and Reproductive Medicine (Z.S., G.B.), Department of Medical Genetics (A.M., N.L., M.G.), Department of Pediatric Radiology (F.B.), Department of Fetopathology (C.J.-P.), University of Caen, Caen, France, Department of Virology, Saint Vincent de Paul Hospital, Paris, France (F.R., P.L.), Department of Genetics, University of Clermont-Ferrand, Clermont-Ferrand, France (I.C.)
| | - Nathalie Leporrier
- Department of Gynecology, Obstetrics, and Reproductive Medicine (Z.S., G.B.), Department of Medical Genetics (A.M., N.L., M.G.), Department of Pediatric Radiology (F.B.), Department of Fetopathology (C.J.-P.), University of Caen, Caen, France, Department of Virology, Saint Vincent de Paul Hospital, Paris, France (F.R., P.L.), Department of Genetics, University of Clermont-Ferrand, Clermont-Ferrand, France (I.C.)
| | - Frédérique Belloy
- Department of Gynecology, Obstetrics, and Reproductive Medicine (Z.S., G.B.), Department of Medical Genetics (A.M., N.L., M.G.), Department of Pediatric Radiology (F.B.), Department of Fetopathology (C.J.-P.), University of Caen, Caen, France, Department of Virology, Saint Vincent de Paul Hospital, Paris, France (F.R., P.L.), Department of Genetics, University of Clermont-Ferrand, Clermont-Ferrand, France (I.C.)
| | - Corinne Jeanne-Pasquier
- Department of Gynecology, Obstetrics, and Reproductive Medicine (Z.S., G.B.), Department of Medical Genetics (A.M., N.L., M.G.), Department of Pediatric Radiology (F.B.), Department of Fetopathology (C.J.-P.), University of Caen, Caen, France, Department of Virology, Saint Vincent de Paul Hospital, Paris, France (F.R., P.L.), Department of Genetics, University of Clermont-Ferrand, Clermont-Ferrand, France (I.C.)
| | - Marion Gérard
- Department of Gynecology, Obstetrics, and Reproductive Medicine (Z.S., G.B.), Department of Medical Genetics (A.M., N.L., M.G.), Department of Pediatric Radiology (F.B.), Department of Fetopathology (C.J.-P.), University of Caen, Caen, France, Department of Virology, Saint Vincent de Paul Hospital, Paris, France (F.R., P.L.), Department of Genetics, University of Clermont-Ferrand, Clermont-Ferrand, France (I.C.)
| | - Flore Rozenberg
- Department of Gynecology, Obstetrics, and Reproductive Medicine (Z.S., G.B.), Department of Medical Genetics (A.M., N.L., M.G.), Department of Pediatric Radiology (F.B.), Department of Fetopathology (C.J.-P.), University of Caen, Caen, France, Department of Virology, Saint Vincent de Paul Hospital, Paris, France (F.R., P.L.), Department of Genetics, University of Clermont-Ferrand, Clermont-Ferrand, France (I.C.)
| | - Pierre Lebon
- Department of Gynecology, Obstetrics, and Reproductive Medicine (Z.S., G.B.), Department of Medical Genetics (A.M., N.L., M.G.), Department of Pediatric Radiology (F.B.), Department of Fetopathology (C.J.-P.), University of Caen, Caen, France, Department of Virology, Saint Vincent de Paul Hospital, Paris, France (F.R., P.L.), Department of Genetics, University of Clermont-Ferrand, Clermont-Ferrand, France (I.C.)
| | - Isabelle Creveaux
- Department of Gynecology, Obstetrics, and Reproductive Medicine (Z.S., G.B.), Department of Medical Genetics (A.M., N.L., M.G.), Department of Pediatric Radiology (F.B.), Department of Fetopathology (C.J.-P.), University of Caen, Caen, France, Department of Virology, Saint Vincent de Paul Hospital, Paris, France (F.R., P.L.), Department of Genetics, University of Clermont-Ferrand, Clermont-Ferrand, France (I.C.)
| | - Guillaume Benoist
- Department of Gynecology, Obstetrics, and Reproductive Medicine (Z.S., G.B.), Department of Medical Genetics (A.M., N.L., M.G.), Department of Pediatric Radiology (F.B.), Department of Fetopathology (C.J.-P.), University of Caen, Caen, France, Department of Virology, Saint Vincent de Paul Hospital, Paris, France (F.R., P.L.), Department of Genetics, University of Clermont-Ferrand, Clermont-Ferrand, France (I.C.)
| |
Collapse
|
41
|
Marcato L, Turolla L, Pompilii E, Dupont C, Gruchy N, De Toffol S, Bracalente G, Bacrot S, Troilo E, Tabet AC, Rossi S, Delezoïde AL, Baldo D, Leporrier N, Maggi F, Molin A, Pilu G, Simoni G, Vialard F, Grati FR. Prenatal phenotype of Williams-Beuren syndrome and of the reciprocal duplication syndrome. Clin Case Rep 2014; 2:25-32. [PMID: 25356238 PMCID: PMC4184624 DOI: 10.1002/ccr3.48] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2013] [Accepted: 01/03/2014] [Indexed: 12/25/2022] Open
Abstract
Key Clinical Message Copy losses/gains of the Williams–Beuren syndrome (WBS) region cause neurodevelopmental disorders with variable expressivity. The WBS prenatal diagnosis cannot be easily performed by ultrasound because only few phenotypic features can be assessed. Three WBS and the first reciprocal duplication prenatal cases are described with a review of the literature.
Collapse
Affiliation(s)
- Livia Marcato
- Research and development, cytogenetics and molecular biology, TOMA Advanced Biomedical Assays Busto Arsizio, Varese, Italy
| | - Licia Turolla
- Unit of medical genetics, ULSS 9 Treviso Hospital Treviso, Italy
| | - Eva Pompilii
- Unit of medical genetics, St. Orsola Malpighi Hospital, University of Bologna Bologna, Italy ; Gynepro Medical Bologna, Italy
| | - Celine Dupont
- Department of Cytogenetics and Developmental Biology, Robert Debré Hospital, Paris and University Paris 7 Diderot Paris, France
| | - Nicolas Gruchy
- Deparment of Genetics, CHU Caen Côte de Nacre, UFR de Médecine Caen Caen, France
| | - Simona De Toffol
- Research and development, cytogenetics and molecular biology, TOMA Advanced Biomedical Assays Busto Arsizio, Varese, Italy
| | | | - Severine Bacrot
- Department of Cytogenetics and Developmental Biology, Robert Debré Hospital, Paris and University Paris 7 Diderot Paris, France
| | | | - Anne C Tabet
- Department of Cytogenetics and Developmental Biology, Robert Debré Hospital, Paris and University Paris 7 Diderot Paris, France
| | - Sabrina Rossi
- Unit of Anatomy pathology, histology, cytodiagnostics and cytogenetics, ULSS 9 Treviso Hospital Treviso, Italy
| | - Anne L Delezoïde
- Department of Cytogenetics and Developmental Biology, Robert Debré Hospital, Paris and University Paris 7 Diderot Paris, France
| | - Demetrio Baldo
- Unit of medical genetics, ULSS 9 Treviso Hospital Treviso, Italy
| | - Nathalie Leporrier
- Deparment of Genetics, CHU Caen Côte de Nacre, UFR de Médecine Caen Caen, France
| | - Federico Maggi
- Research and development, cytogenetics and molecular biology, TOMA Advanced Biomedical Assays Busto Arsizio, Varese, Italy
| | - Arnaud Molin
- Deparment of Genetics, CHU Caen Côte de Nacre, UFR de Médecine Caen Caen, France
| | - Gianluigi Pilu
- Gynepro Medical Bologna, Italy ; Department of Obstetrics and Gynecology, St. Orsola Malpighi Hospital, University of Bologna Bologna, Italy
| | - Giuseppe Simoni
- Research and development, cytogenetics and molecular biology, TOMA Advanced Biomedical Assays Busto Arsizio, Varese, Italy
| | - Francois Vialard
- Department of Cytogenetics, Fetopathology, Obstetrics and Gynaeacology, CHI Poissy St Germain Poissy, France
| | - Francesca R Grati
- Research and development, cytogenetics and molecular biology, TOMA Advanced Biomedical Assays Busto Arsizio, Varese, Italy
| |
Collapse
|
42
|
Richard N, Molin A, Coudray N, Rault-Guillaume P, Jüppner H, Kottler ML. Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLαs in fetal development. J Clin Endocrinol Metab 2013; 98:E1549-56. [PMID: 23884777 PMCID: PMC3763972 DOI: 10.1210/jc.2013-1667] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
CONTEXT Heterozygous GNAS inactivating mutations cause pseudohypoparathyroidism type Ia (PHP-Ia) when maternally inherited and pseudopseudohypoparathyroidism (PPHP)/progressive osseous heteroplasia (POH) when paternally inherited. Recent studies have suggested that mutations on the paternal, but not the maternal, GNAS allele could be associated with intrauterine growth retardation (IUGR) and thus small size for gestational age. OBJECTIVES The aim of the study was to confirm and expand these findings in a large number of patients presenting with either PHP-Ia or PPHP/POH. PATIENTS AND METHODS We collected birth parameters (ie, gestational age, weight, length, and head circumference) of patients with either PHP-Ia (n = 29) or PPHP/POH (n = 26) with verified GNAS mutations. The parental allele carrying the mutation was assessed by investigating the parents or, when a de novo mutation was identified, through informative intragenic polymorphisms. RESULTS Heterozygous GNAS mutations on either parental allele were associated with IUGR. However, when these mutations are located on the paternal GNAS allele, IUGR was considerably more pronounced than with mutations on the maternal allele. Moreover, birth weights were lower with paternal GNAS mutations affecting exons 2-13 than with exon 1/intron 1 mutations. CONCLUSIONS These data indicate that a paternally derived GNAS transcript, possibly XLαs, is required for normal fetal growth and development and that this transcript affects placental functions. Thus, similar to other imprinted genes, GNAS controls growth and/or fetal development.
Collapse
Affiliation(s)
- Nicolas Richard
- Centre Hospitalier Universitaire de Caen, Department of Genetics, Reference Centre for Rare Disorders of Calcium and Phosphorus Metabolism, F-14000 Caen, France
| | | | | | | | | | | |
Collapse
|
43
|
Molin A, Benoist G, Jeanne-Pasquier C, Elkartoufi N, Litzer J, Decamp M, Gruchy N, Durand-Malbruny M, Begorre M, Attie-Bitach T, Leporrier N. 12q21 Microdeletion in a fetus with Meckel syndrome involving CEP290/MKS4. Eur J Med Genet 2013; 56:580-3. [PMID: 23954617 DOI: 10.1016/j.ejmg.2013.08.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2013] [Accepted: 08/02/2013] [Indexed: 01/15/2023]
Abstract
We report on a fetus with Meckel syndrome diagnosed during the 21st gestational week, hydrocephalus and bilateral hyperechogenic kidneys were then detected on ultrasonography. Fetal pathological examination showed facial dysmorphism, occipital meningoencephalocele, characteristic renal cysts, mild hepatic ductal dysplasia, hydrocephalus in association with extreme cerebellar vermis hypoplasia and brainstem anomalies. Molecular and cytogenetic analysis identified a paternally inherited CEP290/MKS4 (MIM611134) (12q21) nonsense mutation and a maternal 12q21 microdeletion. Two cases with such a mechanism have previously been described in the literature, one of them involves an inherited microdeletion. The observation of such cases highlights the existence of a pathogenic mechanism which involves deletion and point mutation, and illustrates how homozygosity can hide hemizygosity when usual sequencing methods are used. The identification of hemizygosity enables to determine precisely the molecular mechanism and to understand some phenotypic variations. As they act as complete loss of function allele, deletions might give indication on the severity of the associated point mutation. This clinical report highlights the importance of fetal pathology following termination of pregnancies in order to guide molecular analysis and the potential role of cytogenetic cryptic disorders in autosomal recessive disease. The use of polymorphic marker analysis in association with FISH or arrayCGH provided an accurate identification of molecular mechanisms, accurate genetic counseling and optimized strategy for next pregnancies or preimplantation diagnosis.
Collapse
Affiliation(s)
- Arnaud Molin
- Service de Génétique, laboratoire de Cytogénétique, CHU de Caen, Université Caen Basse-Normandie, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Maksimenko O, Pavlov E, Toushov E, Molin A, Stukalov Y, Prudskova T, Feldman V, Kreuter J, Gelperina S. Radiation sterilisation of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 2008; 356:325-32. [DOI: 10.1016/j.ijpharm.2008.01.010] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2007] [Revised: 12/23/2007] [Accepted: 01/05/2008] [Indexed: 11/16/2022]
|
45
|
Molin A, Nordström A, Bergström S. [Changed abortion policy in the USA will result in increased maternal mortality globally]. Lakartidningen 2001; 98:2727-8. [PMID: 11430232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
|
46
|
Abstract
Experience of 32 cases of symphysiotomy carried out in Mozambique and in Botswana is reviewed. Of all cases only 1 was lost to follow-up. The observation period varied from 7 days to 6 months. Among 31 cases examined at discharge or on return from check-up few complications occurred. Vaginal laceration occurred in 3 cases, haematuria in 1 case and wound infection in 1 case. In 2 cases there was significant postoperative pain causing gait problems, but in no case were there significant problems with pain at discharge or at follow-up. It is concluded that the intervention is seldom complicated by severe sequelae, provided strict adherence to given indications is respected. In rural areas in the third world symphysiotomy is a life-saving and simple surgical intervention, which should be regarded as an adjunct measure in some cases with a moderately contracted pelvic outlet incompatible with normal vaginal delivery.
Collapse
Affiliation(s)
- S Bergström
- Department of Obstetrics and Gynecology, University Hospital, Uppsala, Sweden
| | | | | |
Collapse
|
47
|
Abstract
A fall in cervical resistance to dilatation for first-trimester-induced abortions has been observed in previous studies and considered a sign of tearing of the cervical tissue. In a study of 104 patients undergoing first-trimester abortion a fall in resistance was found in 12.5% of women in whom the cervix was dilated to 9 mm, and in 66.7% when dilatation reached 11 mm. No difference between parous and nulliparous women was found.
Collapse
Affiliation(s)
- A Molin
- Department of Obstetrics and Gynaecology, Karolinska Institutet, Danderyd Hospital, Sweden
| |
Collapse
|
48
|
Abstract
Cervical resistance to dilatation was measured in 76 patients undergoing first trimester legal abortion; a specially designed force-sensing instrument was used. No correlation between cervical resistance and patient age or gestational age was found. Increasing parity and earlier legal abortions were significantly correlated with a lowering of the cervical resistance. In patients dilated to 11 mm a lowering of resistance was noted suggesting a tear in cervical tissue.
Collapse
Affiliation(s)
- A Molin
- Department of Obstetrics and Gynaecology, Karolinska Institute, Danderyds Hospital, Sweden
| | | |
Collapse
|
49
|
Molin A, Alvarez Sabín J, Malagelada A, Codina A. [Hemiparesis-ataxia in meningovascular syphilis]. Neurologia 1992; 7:190-3. [PMID: 1419089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Two cases of lacunar infarction of "ataxic-hemiparesis" type secondary to luetic vasculitis are presented. The first patient presented meningovasculitis and the second progressive general paralysis. In both cases the ischemic lesion was seen by magnetic resonance and was located at a pontine level in one case and in the corona radiata in the other. Treponemal serology in plasma and CSF was positive in both cases with lymphocytic pleocytosis and high CSF protein levels being observed. Clinical and response to treatment was satisfactory except in the case of general paralysis in whom the impairments existing prior to the cerebral infarction persisted. This study complements recent communications in which neurosyphilis was attributed to the appearance of other lacunar type infarctions (pure motor hemiparesis).
Collapse
Affiliation(s)
- A Molin
- Servicio de Neurología, Hospital General de la Vall d'Hebron, Universidad Autónoma, Barcelona
| | | | | | | |
Collapse
|
50
|
Molin A, Brundin J. Cervical dilatation before first trimester elective abortion: a comparison between laminaria and a newly developed hydrogel tent, the A rod. Gynecol Obstet Invest 1992; 34:12-4. [PMID: 1526524 DOI: 10.1159/000292716] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The effect of cervical dilatation prior to first trimester abortion by laminaria tent and a newly developed hydrogel tent, the A rod, was studied on 50 patients undergoing first trimester legal abortion. The effect was measured both clinically and by the use of an objective measure of cervical resistance. No significant difference in cervical dilatation was found after 5 h of treatment.
Collapse
Affiliation(s)
- A Molin
- Department of Obstetrics and Gynecology, Karolinska Institutet, Danderyds Hospital, Sweden
| | | |
Collapse
|